

TENDER NO: -60(20-21)/APMSIDC/Medicine Wing/2020-22, Dated: 03.06.2020.

TENDER FOR SUPPLY OF DRUGS

To

**ANDHRA PRADESH MEDICAL SERVICES &**

**INFRASTRUCTURE DEVELOPMENT CORPORATION**

for the year 2020-22

(Finalization of Rate Contract for Two years

from the date of Price bid approval)

**ANDHRA PRADESH MEDICAL SERVICES &**

**INFRASTRUCTURE DEVELOPMENT CORPORATION**

(AN ENTERPRISE OF GOVT. OF A.P.),

Plot No.9, Survey No.49, IT Park, Mangalagiri,

Guntur District – 522 503.

ANDHRA PRADESH

**URL:** [**http://msidc.ap.nic.in**](http://msidc.ap.nic.in)

ONLINE TENDER FOR THE SUPPLY OF DRUGS TO APMSIDC

|  |  |  |
| --- | --- | --- |
| **S. No** | **Information** | **Details** |
| **1** | Bid Reference | **60(20-21)/APMSIDC/Medicine Wing/2020-22, Dated: 03.06.2020(General Medicines)** |
| **2** | Date and time for downloading bid document | From 17-6-2020,11.00 am |
| **3** | Last date for submission of queries through online only. | 23-06-2020 at 5.00 pm |
| **4** | Pre- bid queries | All Prebid queries to be sent on [tenders.apmsidc@gmail.com](mailto:tenders.apmsidc@gmail.com) |
| **5** | Last date and time for uploading Documents | 03-07-2020 at 5.00 pm |
| **6** | Date and time of opening of Online technical bids | 03-07-2020 at 5.01 pm |
| **7** | Last date and time of submission of offline documents | 06-07-2020 at 5.00 pm |
| **8** | Tender Processing Fee | The bidder shall remit processing fee Rs. 5625/- in the form of Demand Draft in the name of The Managing Director, APMSIDC, Mangalagiri. |
| **9** | Earnest Money Deposit (EMD) | The Earnest Money Deposit (EMD) in the form of Demand Draft or Bank Guarantee or Bankers Chequefor Rs.3,00,000/- in favour of Managing Director, APMSIDC, Mangalagiri, Guntur district. |
| **10** | E-mail | [tenders.apmsidc@gmail.com](mailto:tenders.apmsidc@gmail.com), apmsidc.gm@gmail.com |
| **11** | Contact number | General Manager- Drugs :8978680705 |

The tender document can be downloaded free of cost from the e-Procurement Portal https://tender.apeprocurement.gov.in/ and from the website of APMSIDC [www.msidc.ap.nic.in](http://www.msidc.ap.nic.in).

Table of Contents

[1. LAST DATE AND TIME FOR SUBMISSION OF ONLINE TENDERS 5](#_Toc42894104)

[2. ELIGIBILITY CRITERIA 5](#_Toc42894105)

[3. GENERAL CONDITIONS 6](#_Toc42894106)

[4.TECHNICAL BID 7](#_Toc42894107)

[5.PRICE BID 9](#_Toc42894108)

[6.OPENING OF TENDER 9](#_Toc42894109)

[7. EARNEST MONEY DEPOSIT 10](#_Toc42894110)

[8. OTHER CONDITIONS 10](#_Toc42894111)

[9. ACCEPTANCE OF TENDER 12](#_Toc42894112)

[10.PERFORMANCE SECURITY DEPOSIT 13](#_Toc42894113)

[11.METHODOLOGY FOR PLACING ORDERS 14](#_Toc42894114)

[12. SUPPLY CONDITIONS 15](#_Toc42894115)

[13. LOGOGRAMS 17](#_Toc42894116)

[14.PACKING 18](#_Toc42894117)

[15. QUALITY TESTING 19](#_Toc42894118)

[16. PAYMENT PROVISIONS 20](#_Toc42894119)

[17.TESTING CHARGES 21](#_Toc42894120)

[18.LIQUIDATED DAMAGES AND OTHER PENALTIES 22](#_Toc42894121)

[19.DEDUCTION & OTHER PENALTIES ON ACCOUNT OF QUALITYFAILURE: 22](#_Toc42894122)

[20. BLACKLISTING CRITERIA 24](#_Toc42894123)

[20.1. BLACKLISTING OF PRODUCT/TENDERER ON WITHDRAWAL OF TENDER 24](#_Toc42894124)

[20.2. BLACKLISTING FOR QUALITY FAILURE 24](#_Toc42894125)

[20.3 BLACKLISTING FOR NON-SUPPLY 26](#_Toc42894126)

[20.5 APPEAL (s) IN CASE OF BLACKLISTING: 27](#_Toc42894127)

[21.SAVING CLAUSE 27](#_Toc42894128)

[22.RESOLUTION OF DISPUTES 28](#_Toc42894129)

[23. FRAUDULENT AND CORRUPT PRACTICES: 28](#_Toc42894130)

[24. JURISDICTION 29](#_Toc42894131)

[ANNEXURE -I 30](#_Toc42894132)

[ANNEXURE -II 34](#_Toc42894133)

[ANNEXURE-III 35](#_Toc42894134)

[ANNEXURE- IV 36](#_Toc42894135)

[ANNEXURE- V 38](#_Toc42894136)

[ANNEXURE -VI 40](#_Toc42894137)

[ANNEXURE -VII 41](#_Toc42894138)

[ANNEXURE IX 42](#_Toc42894139)

[ANNEXURE - X 43](#_Toc42894140)

[ANNEXURE - X1 (A) 44](#_Toc42894141)

[Enclosure-1 to ANNEXURE - X1 AND X1 (A) 45](#_Toc42894142)

[ANNEXURE-XII 46](#_Toc42894143)

[ANNEXURE –XIII 50](#_Toc42894144)

[ANNEXURE-XIV 52](#_Toc42894145)

[ANNEXURE –VIII 53](#_Toc42894146)

ONLINE TENDER FOR THE SUPPLY OF DRUGS TO APMSIDCFOR THE YEARS2020-22

APMSIDC is responsible for procurement and supply of all essential Medicines & Surgical Consumables to the Government Health facilities of A.P., to ensure availability of medicines on free of cost. The main functions of the Corporation are Construction & Maintenance of Hospital Buildings. Further, the Procurement and distribution of Drugs, Surgicals& Consumable and Equipment is also entrusted to this Corporation by the Government (Medical and Health Department). The Corporation is functioning on No Profit and No Loss basis.

**Purchaser/Tender Inviting Authority** - Managing Director, APMSIDC, Mangalagiri-522503, Guntur District, Andhra Pradesh (hereinafter referred as Tender Inviting Authority unless the context otherwise requires).

**Purchaser/Tender Accepting Authority** - Managing Director, APMSIDC, (hereinafter referred as APMSIDC unless the context otherwise requires).

Tender Inviting Authority invites Tender for the supply of Drugs to APMSIDC, for the years 2020-2022.

# 1. **LAST DATE AND TIME FOR SUBMISSION OF ONLINE TENDERS**

1. Online Bids and price bid will be submitted on AP e-procurement portal i.e. <https://tender.apeprocurement.gov.in/>
2. The price bid shall be valid for a period of 120 days from the date of opening of Technical Bid. Prior to the expiry of the bid validity, the Tender Inviting Authority may request the Tenderers to extend the bid validity for further period as deemed fit on their original quoted prices and all terms &conditions.

# **2. ELIGIBILITY CRITERIA**

1. Entity of the bidder should be as follows:
2. The Bidder/Tenderer shall be a manufacturer having valid drug manufacturing unit duly licensed by licensing authorities. Manufacturer should have valid GMP/WHO-GMP (World Health Organisation-Good Manufacturing Practices) certificate issued by licensing authority.

(OR)

1. Tenderer shall be direct importer holding valid import license. The manufacturer of foreign supplier should be WHO-GMP certified company. The Importer should have valid sale license and should submit valid WHO-GMP of the manufacturer.
2. (iii)Distributors/Suppliers/Marketer/Agents are not eligible to participate in the Tenders.
3. An originalcertificate from C.A. (Chartered Accountant) or Company Secretary that:

**I.** Average Annual turnover of manufacturer in the lastthree years i.e. 2016-17, 2017-18 and 2018-19shall not be less than Rs.10 Crores. In case of Small-scale industries situated in the state of Andhra Pradesh the turnover shall not be less than Rs. 5 Crores.

II.(a) Non-conviction Certificate not older than 12 months issued by the licensing authority of the State certifying that the firm/company has not been convicted.

(b)Tenderer should not be submitted for the product(s) for which the firm / company has beenblacklisted/debarred/de-registered/banned by any State Government / Central Government / its Drug procurement agencies due to quality failure of the drugs at the time of submission of online bid.

(c)Further, quoted drugs have not been failed in house testing or testing by any State Government/Central Government / its Drug procurement agencies/APMSIDC during last two years.

(d)During the validity of the tender, if the firm / Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government / its Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to APMSIDC along with relevant authentic document by the tenderer firm/ company within one month otherwise a penalty of Rs 1,00,000/-shall be imposed on the firm by APMSIDC.

(e)The tenderer should confirm that they have read tender document including Amendment(s)to Tender document (if any) along with terms and condition and these terms and condition of tender document including Amendment(s) to Tender document (if any) are acceptable unconditionally to them.

# **3****. GENERAL CONDITIONS**

1. The tender document shall be downloaded from the websites http://msidc.ap.nic.in/;and portal i.e.apeprocurement.gov. in. Tender Document is free of cost. The bidder shall remit processing fee Rs. 5625/- in the form of Demand Draft in the name of The Managing Director, APMSIDC, Mangalagiri.
2. EMD (Earnest Money Deposit): EMD of Rs.3,00,000/- (Rupees Three Lakhs only as specified in Clause 7 of the Tender document in the form of Demand Draft or Bank Guarantee or Bankers Cheque from nationalised/Scheduled Bank favoring "MD, APMSIDC", payable at Mangalagiriwhich is to be delivered in original toAPMSIDC, Mangalagiri on or before the date stipulated against ' Bid opening Date '. Name &full address of the bidder may be written at the back of the Demand Draft/Pay Order. Signed and scanned soft copy of the EMDinstrument must be uploaded (ANNEXURE III) to the e-Procurement portal. EMD in any other form like cheque/cash/postal order etc. will not be accepted. The Bid (in case not exempted for EMD as mentioned in tender document) without EMD shall be summarily rejected.
3. (a) At any time prior to the last date of submission of online bid, Tender Inviting Authority may, for any reason, whether on own initiative or in response to a clarification requested by a prospective Tenderer, may modify the condition in Tender documents by an amendment uploading on website on msidc.ap.nic.in;and AP e-Procurement portal i.e. **ap**eprocurement.gov.inwill be binding on them. In order to provide reasonable time to take the amendment into account in preparing their bid, Tender Inviting Authority may at discretion, extend the date and time for submission of online bid.

(b) Any person who has downloaded the tender document should watch for amendment, if any, on the website msidc.ap.nic.in;and AP e-Procurement Portal i.e.**ap**eprocurement.gov.infor which APMSIDC will not issue any separate communication to them.

1. During tender or price agreement period, if L1 bidder is debarred/deregistered/blacklisted/banned by any Central Government or state Government or its procurement agencies due to quality failure, APMSIDC may purchase the drugs from L2 bidder who shall match the price of L1 or may go for fresh tender as per discretion of APMSIDC.

3.1 SPECIAL CONDITIONS

(i)Bids shall be submitted online only at procurement portalwebsite:<https://apeprocurement.gov.in>. Manual bids shall not be accepted except for the original documents/instruments as mentioned in tender document.

(ii)Bidder shall not modify the downloaded tender form including downloaded price Bid template in any manner. In case any tender form/Price bid template is found to be tampered with/modified in any manner, such bid will be summarily rejected, Bid Security would be forfeited, and bidder is liable to be banned from doing business with APMSIDC.

(iii)Bidders are advised to check the website of APMSIDC: msidc.ap.nic.in and Procurement portal website <https://apeprocurement.gov.in> prior to closing date of submission of tender for any corrigendum, addendum, or amendment to the tender document.

# **4.TECHNICAL BID**

4.1. The Tenderer should upload the following documents while submitting technical bid. (Scanned copies of each page of all documents should be uploaded while submitting Technical bid) by referring them in Index.

1. The tenderers are required to upload scanned undertaking on stamp paper duly notarized byauthorised signatory (ANNEXURE - II) confirming each clause mentioned in Section 2 of eligibility criteria.
2. In case the bidder is Importer, they may strike the clause or part of clause not applicable in their case. The drugs indicated in this undertaking shall only be considered for evaluation and opening of price bid.
3. On the basis of such undertaking, the price bid shall be opened within a week after opening of technical bid. However, the bidder is required to upload/submit all the documents along with the technical bid and incase any document is not complying as per undertaking, their contract/Price agreement shall be cancelled with forfeiture of EMD/Performance security deposit/Bank guarantee.
4. Offline documents with original ANNEXURE - II in sealed cover should be submitted to APMSIDC, Mangalagiri on or before the scheduled date.
5. Earnest Money Deposit as indicated in Clause 3(ii) and Clause 7. of the tender document shall be in the form of Bank Guarantee or Bankers Cheque or Demand Draft favoring "MD, APMSIDC "payable at Mangalagiri. Tender cost and EMD in any other form like cheque/cash/postal order etc. will not be accepted. Scanned soft copy of the EMD instrument must be uploaded (ANNEXURE - III) to the e-Procurement portal. and original EMD instrument should be submitted to APMSIDC, Mangalagiri on or before the schedule date of technical bid opening.
6. The tenderers are required to upload a certificate from the C.A. (Chartered Accountant) or Company Secretary as per ANNEXURE IV.
7. Authorization letter nominating an officer of the Tenderer on the printed letter head of the company to transact the business with the APMSIDC to be uploaded.
8. The Tenderer should upload Scanned copy of valid drug Manufacturing License for the product, duly approved by the Licensing Authority for each and every product quoted as per specification in the tender. The license must have been duly renewed up to date and the items quoted shall be clearly highlighted in the license. Original documents should be produced for verification when demanded. However, if renewal application for manufacturing license has been filed, Scanned copy of same duly receipted by drug authorities must be uploaded along with the validity certificate from state licensing authority (SLA).
9. Scanned copy of import license (in Form 10 with Form 41), as per Rule 122A of the Drugs and Cosmetics Act 1940, if the product is imported should be uploaded. The license must have been renewed up to date. A copy of a valid license for the sale of Drugs imported by the firms issued by the State Licensing Authority shall be uploaded. Original documents should be produced for verification when demanded.
10. The copies of relevant pages approved by drug authorities of concerned country for any quoted Drug/product offering CoPP certificate and quoted drugs/ products manufactured by manufacturing units approved by US FDA, TG Australia, Health Canada, EU approval, MCC South Africa approval, Brazil Anvisa should be uploaded with technical bid.
11. In case of Imported drugs, labels and product literature of all quoted product(s) must be uploaded COPP certificate as per WHO format of their Principal Manufacturing company/firm.
12. Documents, if any, to show that the manufacturing unit/importer has been recognized by any other Indian / International Standard Organizations etc. as applicable. Importer should upload WHO-GMP certificate of manufacturer.
13. A Checklist (ANNEXURE- V) shall be uploaded with technical bid. If a company/firm has two or more separate manufacturing units at different sites / States, which are not separate entities then the company will be allowed to submit only one tender for all units but necessary document regarding separate manufacturing units will uploaded as a separate set with the same tender. However, one bidder will be allowed to submit only one offer for one product.
14. All the documents uploaded should also be signed by the authorized official of the Tenderer.

# **5.PRICE BID**

5.1. Price Bid of the Tenderer.

(i) The Tenderer shall fill in the rate per unit size inclusive of GST in respective column of BOQ for the items quoted.

(ii)Determination of L1 bidder:

(a)In determining the lowest evaluated price, the rate quoted per unit size inclusive of GST as indicated in price bid shall be taken into consideration and lowest landed price will be taken into consideration for determination of L1 Bidder.

**(b)**Incase where the tender quantity of certain medicines is high then to keep the drug supplies in track the APMSIDC reserves the right to award the contract to L2 bidder if L2 accepts the L1 bidder price. Local SSI units are also permitted to match the L1 price to the extent of 20% of ordered quantity at the sole discretion of APMSIDC.

(iii) The rates quoted should be in Indian Rupees. The Tenderer is not permitted to change/alter specification or unit size given in the ANNEXURE-VII.

(iv)In case no information is given on GST, it shall be presumed that rates are inclusive of GST and no GST shall be charged by them under any circumstances.

# **6.OPENING OF TENDER**

6.1 Technical bid evaluation will be done in the presence of Drugs Inspectors.

6.2 After the completion of Technical evaluation preliminary objections will be published on APMSIDC portal www.**msidc.ap.nic.in** for replies from firms. After scrutiny of these remarks by the technical committee final evaluation will be done.

**6.3**Only the technically qualified firms in the bid will be eligible for opening of price bid.

# **7. EARNEST MONEY DEPOSIT**

7.1. The Earnest Money Deposit referred to under Clause 3(ii) & 4.1(a), shall be Rs. 3 lakhs. The Earnest Money Deposit shall be paid in the form of Bank Guarantee or Bankers Cheque or Demand Draft in favour of APMSIDC, payable at Mangalagiri. In case EMD in form of Bank Guarantee, Irrevocable Bank Guarantee in favour of APMSIDC from any Nationalised/scheduled Bank should be valid for a period beyond 6 months from the date of tender opening. The format of Bank Guarantee is at ANNEXURE-VI. APMSIDC will not pay interest on any deposit held in the form of Bankers Cheque or Demand Draft.

7.2. (i) The tender submitted without sufficient EMD will be summarily rejected.

(ii)The Earnest Money Deposit will be refunded to the successful bidders within 30 days from the date of acceptance of rate for price agreement and on the deposit of Performance security deposit.

(iii)The Earnest Money Deposit (EMD) of the unsuccessful bidders will be returned after finalization of tender with eligible bidder.

(iv)The Earnest Money Deposit (EMD) will be forfeited, if the tenderer withdraws his bid any time after opening of price bid / non submission of Performance security within the period prescribed/non supply of drugs.

(v)The Earnest Money Deposit (EMD) will be forfeited, in case of the lowest bidder, fails to execute the contract or deposit the performance security deposit within the stipulated time. The EMD shall be forfeited if any of the documents found incorrect.

(vi) SSI units situated in AP state are exempted from the payment of EMD.

# **8. OTHER CONDITIONS**

8.1.(i) The details of the required drugs, medicines, etc., are shown in ANNEXURE -VIII. The tender quantity mentioned herein is not a fixed procurement quantity and it is only a tentative requirement and may be increased or decreased by APMSIDC, at its discretion, depending on it is actual need. Though the tentative quantity is indicated in the price agreement, the APMSIDC, will confirm the actual requirement then / there through purchase order/orders. The tenderers shall supply the drugs only on the basis of the purchase order issued time to time within validity of contract period by the APMSIDC. Any supply without a valid purchase order will not be acceptable by APMSIDC and the APMSIDC shall not be responsible for any loss on this account.

(ii) The Tenderer shall fill in manufacturing capacity per year in units, Shelf life in months and manufacturing batch size in units for each quoted drug in required column of ANNEXURE -X and upload along with technical bid. In case the bidder is Importer, the importer is required to sign and upload ANNEXURE X on behalf of the exporter which would be supported by documentary evidence provided by the manufacturer.

(iii)However, once the purchase order/orders is/are issued by the APMSIDC, the tenderer shall not renege from the commitment of supplying the quantity mentioned in the acceptance of tender for price agreement.

(iv)The rates quoted shall not be varied with the ordered quantity during the full contract period.

**8.2**Tender has been called for in the Generic name of drugs. The Tenderers should quote the rates for the generic products only. The composition, strength and packing of each product should be as per specifications given in ANNEXURE-VIII. Any variation, if found, will result in rejection of the tender. However, the imported/combination drugs are allowed to quote in trade / brand name.

**8.3**Rates (inclusive of Customs duty, packing & forwarding charges, transportation, insurance and any incidental charges, all taxes, GST) should be quoted for each of the required drugs, medicines etc., separately on door delivery basis to all 13 Central Drug stores located in District headquarters of AP state according to the unit ordered. Tender for the supply of drugs, medicines, etc. with cross conditions like "AT CURRENT MARKET RATES" shall not be accepted. Handling, clearing, transport charges etc., will not be paid separately. The delivery should be made as stipulated in the purchase order placed with Tenderers.

8.4. Each bid must quote not only the unit rate but also the total value of each item quoted for supply in the respective columns. The aggregate value of all the items quoted in the tender shall also be furnished.

8.5. (i) The price quoted by the tenderers shall not, in any case exceed the Drugs Price Control Order (DPCO) controlled price, if any, fixed by the Central/State Government. Tender Inviting Authority at its discretion, may exercise, the right to revise the price at any stage so as to conform to the controlled price as the case may be. This discretion will be exercised without prejudice to any other action that may be taken against the Tenderer.

(ii) FALL CLAUSE:

If at any time during the execution of the contract, the controlled price becomes lower or the supplier reduces the sale price or sells or offers to sell such stores, as are covered under the contract, to any person / organization including the purchaser or any department of Central government/state Govt. or its procurement agencies at a price lower than the price chargeable under the contract, he shall forthwith notify such reduction or sale or offer of sale to the purchaser and the price payable under the contract for the stores supplied after the date of coming into force of such reduction or sale or offer of sale shall stand correspondingly reduced.

8.6. The rates quoted and accepted will be binding on the Tenderer for the full contract period of two years and any increase in the price will not be entertained till the completion of this contract period. Accordingly, this clause will be applicable for all orders placed during the contract period. However, Price agreement validity period may be extended for period up to further one year at same rate, terms & conditions with the consent of the supplier.

8.7. No Tenderer shall be allowed at any time and on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by them. Representation to make correction in the tender documents on the ground of Clerical error, typographical error, etc., committed by the Tenderers in the Bids shall not be entertained after submission of the tenders. Cross Conditions such as "SUBJECT TO AVAILABILITY", "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the tenders of those who have mentioned such conditions shall be treated as incomplete and accordingly the Tender will be summarily rejected.

8.8. Supplies should be made directly by the tenderer and not through any other Agency / Dealer / Distributors.

8.9. The Tenderer shall allow inspection of the factory at any time after the opening of technical bid and during the entire contract period by a team of Experts/Officials nominated by the Tender Inviting Authority for the purpose. The Tenderer shall extend necessary cooperation to such team in inspection of the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If Company/Firm does not allow for any such inspection, their tenders will be rejected. If any such situation arises after placement of contract, the same shall be cancelled at the firm's risk cost.

8.10 "AP Govt Supply – Not for Sale" should to be printed on each unit/label by the successful bidders. However, this is exempted for imported items.

# **9. ACCEPTANCE OF TENDER**

9.1. (i) Evaluation of the tender and determination of the L1 rate (Lowest rate) will be done based on rate per unit size inclusive of GST as mentioned in column 8 of BOQ.However, to have additional source of supply, the L1 bidder shall be awarded contract/Price agreement for 60% of tender quantity indicated in the tender document. Out of remaining 40%, balance 20% of tender quantity shall be provided to the local MSME/SSI bidder and 20% tender quantity to L2 bidder. In case no local MSME/SSI bidder qualifies then the total 40% of the tender quantity indicated in the tender document shall be awarded to L2 bidder. In either of the above cases, the bidders shall agree to supply the drugs at L1 rates.

(ii) In case, L2 bidder does not agree to match L1 rate, 100% tender quantity shall be awarded to L1 bidder. The purchase order shall be issued to L1 bidder and L2 bidders simultaneously as per discretion of APMSIDC depending upon requirement. In case, order is placed only on L1 bidder and if they fail to supply in stipulated time or due to quality failure, the purchase order shall be issued to L2 bidder.

(iii). Negotiation if required will be done at APMSIDC premises.

Note 2. No undue advantage shall be given for additional quantity to L2 Bidders or MSME while matching/reducing the rate with respect to L1 rate.

9.2. APMSIDC reserves the right to accept or reject the tender for the supply of all or any one or more items of the drugs tendered for in a tender without assigning any reason.

**9.3**APMSIDC or its authorized representative(s) has/have the right to inspect the manufacturing premises of Tenderers, before accepting the rate quoted by them or before releasing any purchase order(s) or at any point of time during the continuance of tender and also has the right to reject the tender or terminate/cancel the purchase orders issued and/or not to place further order, based on adverse reports brought out during such inspections.

**9.4**APMSIDC also reserves right to place one-time purchase order for certain quantity of any drug even without price agreement, for such drugs suppliers are required to pay performance security deposit @ 5 % (Max of 10 Lakhs) of value of order of such drug in the form of DD.

9.5. The acceptance of the tenders for Price Agreement for two years period will be communicated to the Tenderers in writing (ANNEXURE IX).

# **10.PERFORMANCE SECURITY DEPOSIT**

10.1 Performance Security Deposit:

On being informed about the acceptance of the tender for 2 years price agreement, the successful tenderer shall be required to pay a Performance Security Deposit of 5% of the contract value subject to a maximum of Rs.10 lakhs per productin the form of *Demand Draft* drawnin favour of MD, APMSIDC Mangalagiri from any nationalized/scheduled Bank.

10.2. The Tenderer shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons whatsoever.

10.3. All notices or communications relating to and arising out of this price agreement or any of the terms thereof shall be considered duly served on or given to the Tenderer if delivered to him or left at the premises, places of business or abode as provided by the tenderer.

10.4. If the lowest selected Tenderer fails to deposit the required Performance Security Deposit (PSD) within the time specified or withdraws the tender, after the intimation of the acceptance of the tender or owing to any other reasons to undertake the contract, the contract will be cancelled and the Earnest Money Deposit deposited by the tenderer along with the tender shall stand forfeited by the APMSIDC and the firm will also be liable for all damages sustained by the APMSIDC apart from blacklisting and other penal actions.

10.5.The performance security deposit of supplier will be returned after the end of rate contract period by APMSIDC only after the supplier has given undertaking to replace sanitary napkins supplied and indemnify APMSIDC against any losses on account of quality parameters.

10.6. SSI-units situated in A.P are exempted from payment of Performance Security Deposit provided if submitted MSME certificate.

# **11.METHODOLOGY FOR PLACING ORDERS**

For the above purpose the following procedures will be adopted

1. After the conclusion of Price Bid opening, the rates offered by tenderers for each product are evaluated and lowest acceptable rate (L1 Rate) arrived at is declared and that tenderer is informed.
2. The successful Tenderer is eligible for the placement of Purchase Orders only after depositing the required amount as Performance Security.
3. If two or more than two Tenderer's are declared as lowest suppliers for the same item(s), such Tenderers are eligible for price agreement and the placement of Purchase Orders for such item(s) for which they are declared as lowest. Placement of order shall be shared equally amongst these bidders’ subject to their manufacturing capacity.
4. In the case of purchase of goods where the quantity offered at the lowest price is less than the total quantity required, the APMSIDC may, after placing orders with the lowest evaluated Tenderer for the entire quantity offered by such Tenderer subject to his ability to supply, require all the other eligible Tenderers who participated in the tender and offered a price higher than that offered by the lowest evaluated Tenderer, to submit sealed offers of the quantity they would be willing to supply at the price quoted by the lowest evaluated Tenderer, and thereafter place orders for the remaining required quantity with all those who match the lowest evaluated price such that those who bid lower prices in the original tender get a higher priority for supply.
5. If a supplier fails to execute supply order (0% execution) Performance Security Deposit of the product mentioned in purchase order shall be forfeited.
6. Notwithstanding anything contained in para (e) above, the supplier, after committing the default in supply either partly or fully, can inform the APMSIDC about his willingness to execute the Purchase Order during the tender period. The MD, APMSIDC at discretion may consider the willingness of the supplier on merit. However, such supplies will be subjected to the levy of Liquidated Damages, unexecuted fine and other penalties as stipulated in the tender document, price agreement and purchase order, at the discretion of MD, APMSIDC.
7. The supplier shall start supply of the Drugs/Medicines required by APMSIDC at 13 Central Drug Stores (CDS), in Andhra Pradesh or any other place decided by APMSIDC within the stipulated period.
8. The Drugs/Medicines supplied in excess of the ordered quantity shall not be accepted and the supplier shall take back the excess at their cost. APMSIDC will not be responsible for the loss to the supplier and will not entertain any demand/claim.
9. After completion of the supplies the documents related to Tax invoice, Analytical test reports of supplied batches or any other document shall be uploaded on eAushadhi application online for proper acknowledgement of stocks. APMSIDC will not be responsible for any delay in uploading the documents by the supplier which may lead to unforeseen penalties or any wrong entries due to typographical errors, will be allowed for correction within 3 days only.
10. It is the duty of the supplier to supply Drugs/Medicines at the 13 CDS in AP or any other place decided by APMSIDC and supply shall conform to the conditions mentioned in the provisions of tender documents, viz., logo, nomenclature, specification etc. having a minimum of 3/4th of the shelf life.
11. APMSIDC reserves the right to place up to 50% additional purchase order of the quantities as contracted within validity of contract.

# **12. SUPPLY CONDITIONS**

12.1. Purchase orders will be issued to the Tenderer(s) at the discretion of the MD, APMSIDC as per actual requirements. All the supplies shall be received at the 13 CDS in AP or any other place decided by APMSIDC.

12.2. Within 4 days from the receipt of purchase orders, the Tenderer should inform APMSIDC through eAushadhi for the receipt of the purchase order.

12.3. The Tenderer should also Communicate and mail the details of supply dates as specified in Annexure, to APMSIDC within 7 days from the receipt of the purchase order. In case, the supply shall not be made by the date as conveyed by the supplier, supply order shall be cancelled at their risk and cost. If no response is received within 7 days from the supplier / tenderer about supply of drugs as per purchase order, it shall be presumed that the supplier/tenderer is not interested to supply the drugs ordered as per purchase order and APMSIDC shall purchase the drugs from alternative sources.

12.4. Supplies against a purchase order shall be completed within 75 days otherwise liquidated damages are levied by APMSIDC as mentioned in clause 18.1.

If the Tenderer fails to execute the supply within the stipulated time, the APMSIDC is at liberty to make alternative arrangement for purchase of the items for which the Purchase orders have been placed, from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the defaulted supplier and in such cases the APMSIDC has every right to recover the cost and impose Liquidated Damages as mentioned in Clause 18. In case of any variation in prices during alternative procurement will be charged to L1 bidder or defaulted supplier.

12.5. The liquidated damages as specified in clause 18.1 and 18.2 of the tender conditions will be levied. However, the supplier must take prior approval from APMSIDC for supply of drugs beyond stipulated delivery period of the Purchase order or in case of special case to proceed with or without penalty will be at the discretion of MD, APMSIDC.

12.6. The Tenderer must submit an Analysis report for every batch of drug along withinvoice. In case of failure on part of the supplier to furnish such report, the batch of drugs will be returned to the suppliers and he is bound to replenish the same with Govt. approved lab test report. The Drugs supplied by the successful Tenderer shall be of the best quality and shall comply with IP/BP/USP and the specifications, stipulations and conditions specified in the tender.

12.7. Tenderer should supply the product (a) within 2 months excluding month of manufacture of products having shelf life up to 1 or 2 years, (b) within 3 months excluding month of manufacture of products having shelf life more than 2 years & up to 3 years and (c) within 4 months excluding month of manufacture of products having shelf life more than 3 years (d) Within 3.5 months excluding month of manufacture of products for Rabies Vaccine Inj. 2.5 IU. Products beyond the above-mentioned period from the date of manufacture shall not be accepted. For example, product having manufacturing of November 2019 must be supplied by 31stJanuary 2020 in case shelf life less than 2 Years. For imported products, 20 months of shelf life should be available at the time of supply.

12.8. If at any time the Tenderer has, in the opinion of the APMSIDC delayed the supply of drugs due to one or more reasons related to Force Majeure events such as riots, mutinies, wars, fire, storm, tempest, floods or other exceptional events at the manufacturing premises, the time for supplying the drugs may be extended by the MD, APMSIDC at discretion for such period as may be considered reasonable. However, such extension shall be considered only if a specific written request is made by the Tenderer within 20 days from the date of occurrence of such event with necessary documentary evidence. The exceptional events do not include the Increase in the cost of raw material, Electricity failure, Labour disputes/Strikes, Insolvency, and Closure of the Factory/Manufacturing unit on any grounds etc.

12.9. The supplier shall not be liable to pay LD and forfeiture of performance security deposit for the delay in executing the contract on account of the extension of supply period on the ground of force majeure events.

12.10. Suppliers are required to supply the drugs within the delivery period mentioned in the purchase order. In this regard it is informed to the bidders that their performance shall be considered unsatisfactory in case of delayed supply (beyond delivery period) or non-supply of products. APMSIDC may reject their bid in future tenders considering their unsatisfactory performance of supplies.

12.11. If APMSIDC observes some physical defects(like empty blisters, improper labelling) of the supplies during sampling, the batch shall be rejected. If supplier wants to take back the batch for rectification, they can take back at their cost, rectify and send back to APMSIDC within 10 days otherwise same batch shall not be accepted. Due to rectification, if its shelf life condition as per tender provision does not meet, it shall be discretion of APMSIDC depending upon requirement to accept the goods with or without penalty.

12.12. If the drug is not consumed prior to its expiry date i.e., six months before expiry, the supplier will be notified about the short expiry drugs, upon receipt of such information the supplier should replace (at own cost of supplier to and fro) the short expiry/expired quantity with fresh stock of longer shelf life, otherwise the value equal to the cost of expired quantity will be deducted from the bills or any other amount payable to the firm.

# **13. LOGOGRAMS**

Logogram means, wherever the context occurs, the design as specified in ANNEXURE-I. The name of the drug shall be mentioned in English /Teluguas per pharmacopoeia and its strength.

13.1. Tenders for the supply for Drugs etc., shall be considered only if the Tenderer gives an undertaking that the product(s) will be prepared as per the specifications such as name, strength, minimum size and packed with appropriate size of the strips/blisters/bottles/tubes etc. as per the design enclosed as per ANNEXURE -I.

13.2. All dosage form has to be supplied in packing as specified in product list (ANNEXURE VIII) and shall also conform to Schedule P1 of the Drugs & Cosmetics Act &Rules 1940, wherever it applies. Affixing of stickers and rubber stamps shall not be accepted and supplies will be returned at supplier's cost.

13.3. Vials, Ampoules (more or equal than 5 ml) and Bottles containing the items tendered for should also carry the printed AP logogram of proportionate size.

13.4. Failure to supply Drugs etc., with the printed logogram of proportionate size will be treated as breach of the terms of price agreement / violation of tender conditions. The purchase order shall be cancelled at the risk and cost of the supplier. However, if such failure continuous despite notice, will be viewed as a serious lapse and APMSIDC will initiate suitable action.

13.5. For imported Drugs, the supplies will be accepted as per packing and label by foreign manufacturer in their brand subject to affixing sticker for Logo as approved by APMSIDC.

Tenderers who are not willing to agree to conditions above will be summarily rejected.

# **14.PACKING**

14.1. The drugs shall be supplied in the package specified in ANNEXUREVII and ANNEXURE -XII and the package shall carry the logograms of proportionate size specified in ANNEXURE -XI, XI -A. Non-printing of logograms will be treated as violation of tender conditions and fine of 0.5% of the value of Purchase Order will be deducted from the amount payable as per conditions. In case of emergency to meet the short fall of drugs exemption can be given on penalty of 0.5% with the prior approval of MD, APMSIDC.

14.2. The minimum size of each tablet should be 6.4 mm in diameter and the minimum size of the blister packing/strip packing/Alu-alu packing should be 80mm x 35mm/50mm x 130mm/45mm x 110mm respectively. The drugs in any dosage form to be supplied by the supplier should not be embossed indicating any code no./logo or name of the company. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties.

14.3. The packing in each carton shall be strictly as per the specification mentioned in Annexure-XII. The outer carton/secondary packaging should be of pearl white duplex board (off white/grey is not acceptable) with a minimum of 350 GSM with Gloss laminated packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with pearl white board of 350 GSM (off white/grey is not acceptable). The material to be used for carton should be from virgin chemical pulp. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties. Storage conditions must be indicated on outer label.

14.4. The cap of bottle preparations should not carry the name of the supplier.

14.5. The labels in the case of Injectable preparations should clearly indicate whether the preparations are meant for Intravenous (IV), Intramuscular (IM), Intra Dermal (ID), Subcutaneous (SC) administration etc.

14.6. It should be ensured that only first-hand virgin packaging material of uniform size, including bottle and vial, is used for packing.

14.7. All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia.

14.8. Packing should be able to prevent damage or deterioration during transit.

14.9. In the event of items of drug supplied found to be not as per specifications in respect of their packing and logogram, the APMSIDC is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier. In such cases the APMSIDC has every right to recover the cost and impose penalty as mentioned in Clause 18 & 19.

14.10. Designs of packaging with the logograms shall be subject to approval by APMSIDC within 3 days of receipt of purchase order. Text matter of all type of label must be checked and responsibility shall be of manufacturer. In case of failure of APMSIDC to do so, the supplier may go ahead with the design as per the specification in ANNEXURE XI and XIA.

14.11. The colour of the strength must be different from the colour of the generic name of the drug on primary and secondary packaging and the approval for the same should be taken from the quality/regulatory department while taking artwork approval. The printing ink used should be of good quality (clarity, brightness, contrast) which is easily readable.

# **15. QUALITY TESTING**

15.1. Samples of supplies from each batch will be chosen at the point of dispatch at supplier's site or receipt of supply or distribution/storage points for testing at discretion of APMSIDC. The samples will be sent to different laboratories including Government Drugs Testing Laboratory/NIPER/PSU labs for testing as decided by the APMSIDC. Handling and testing charges will be borne by APMSIDC for the above purpose.

15.1.1 Supplier should send the soft copy of the specifications for all approved drugs and STP (Standard Testing Procedure) for Non- Pharmacopoeia approved drugs by mail to Quality and Regulatory officer of APMSIDC with art work approval for design of packaging with the logogram as per Clause 14.10; if they failed to upload/submit the same with technical bid.

1. The Drugs shall have the active ingredients at the prescribed level as indicated in official compendiums throughout the shelf life period of the drug. The samples will be drawn periodically throughout the shelf life period and if found "Not of Standard Quality", the cost of entire batch paid will be recovered whether consumed fully/partially. Also, action will be initiated for blacklisting as per clause No.19 irrespective of the period of supply. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.
2. In the event of the samples of Drugs supplied fails in quality tests or found to be not as per specifications, the APMSIDC is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier and in such cases the APMSIDC has every right to recover the cost and impose penalty as mentioned in Clause 19.
3. The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the APMSIDC. In case of any complaint in the field, the B.M.R/B.P. R for the particular batch of the product(s) supplied shall be produced when demanded.
4. The products should conform to the standards of IP/BP/USP as the case may be. However, the drugs notified in the IP (amended up to date) shall be accepted only if supplied conforming to the standards outlined in the IP. In case the product is not included in the any of the said compendiums, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing. For imported drugs, respective Country's Pharmacopoeia standards shall be acceptable (even if the product is official in IP).

15.6. The case of admixture of drugs will be treated as a violation of tender conditions and fine will be levied as per clause 19. If such lapses happen more than twice in a tender period such cases will be treated as "Misbranded Drugs".

# **16. PAYMENT PROVISIONS**

16.1. No advance payments towards costs of drugs, medicines etc., will be made to the Tenderer.

16.2. Payments towards the supply of drugs will be made within 60 days from the date of receipt of goods, strictly as per the tender terms and condition. The payment will be made through AP Government Finance portal CFMS / RTGS (Real Time Gross Settlement System)/Core Banking/NEFT. The Tenderer shall furnish the relevant details in original (ANNEXURE -XIII) to make the payment through CFMS/RTGS/Core Banking/NEFT.

16.3. All bills/Invoices should be raised in duplicate and the bills should be drawn as per GST Rules in the name of MD, APMSIDC. Mangalagiri, Andhra Pradesh.

16.4. (i) Payment of 50% for a given purchase order will be made after completion of 75% supplies of ordered quantity and remaining will be paid after completion of 95% of supplies. In case any purchase order is executed partially beyond 75% up to 95% remaining bills will be processed at the discretion of APMSIDC by imposing a penalty of 10% on unexecuted quantity value only.

(ii) The payment for part supply if any will subject to the deduction of liquidated damages, penalty towards unexecuted quantity, risk and cost etc., as per the tender conditions.

16.5. If at any time during the period of contract, the price of tendered items is reduced or brought down by any law or Act of the Central or State Government or by the Tenderer himself, the Tenderer shall be bound to inform the APMSIDC immediately about such reduction in the contracted prices. Tender Inviting Authority is empowered to unilaterally effect such reduction as is necessary in rates in case the Tenderer fails to notify or fails to agree for such reduction of rates.

16.6. In case of any increase of decrease in the GST after the date of submission of tenders and during the tender period, such variation in the GST will be to the account of the APMSIDC. For claiming the additional cost on account of the increase in GST, the Tenderer should produce the proof of having paid additional amount on this account on the goods supplied to APMSIDC from the concerned authorities and also must claim the same in the invoice separately.

However, the basic price structure and the price of the Drugs approved under the tender shall not be altered. Similarly, if there is any reduction in the GST as notified by the Govt., after the date of submission of tender, the Tenderer will be paid based on the unit rate worked out on the basis of the reduced GST without any change in the basic price or the price structure of the drugs approved under the tender. Any increase or decrease inGST will be considered based on the notification issued by the Government.

However, if the firm supplies after originally stipulated delivery period, increase in GST shall be borne by the supplier. In case of decrease in taxes/GST due to statutory variation in taxes/GST, the same shall be passed on by the supplier to the APMSIDC.

Subject to the conditions mentioned in the Purchase Order, Tender Document, Price Agreement and here under, the Supplier is entitled for the payment against supply. In case of any discrepancy in levy of LD, Penalty, Unexecuted Fine, Short Passing of Bills, such discrepancy shall be intimated within 30 days from the date of receipt of payment, failing which APMSIDC will not entertain any claim thereafter.

# **17.TESTING CHARGES**

In all supplies, testing charges will be borne by APMSIDC.

# **18.LIQUIDATED DAMAGES AND OTHER PENALTIES**

18.1. Liquidated damages and penalties -

|  |  |  |
| --- | --- | --- |
| Sr. No. | Penalty | Action |
| 1 | Supply period without penalties | Upto 75 days from the date of issue of PO, supplies shall be started by 45th day from the date of issue of Po |
| 2 | 0.5% per day | For 76thday to 120th days, but not exceeding 10% of the PO value for all other firms except 5% for local AP SSI (Small Scale Industry) Units |
| 3 | PO Cancellation | Beyond 120 days PO will be cancelled and stocks will not be accepted. PSD will be forfeited. Alternate Procurement will be done from the other bidders matching with L1 price or at their quoted price or from the other open sources procurement and difference in procurement will be charged to the L1 supplier |
| 4 | Other penalties | If two POs were not executed, the firm will be declared as "Undependable" for the product and the action will be taken as per clause 20.3 of this tender. |

**18.2**If the supply is received in damaged condition, open delivery of the supplies shall be received, wherein it is possible to physically inspect the shipment, damaged products shall not be accepted.

**18.3**All the Tenderers are required to supply the product(s) with printed “Andhra Pradesh Govt. Supply – Not for Sale” and logogram of appropriate size on the strips, blisters, vials, ampoules& bottles and with prescribed packing specification. If there are any deviations in these Tender conditions, action will be taken to blacklist the product and/or a separate damage will be levied @ 0.5% of value of the defaulted quantity irrespective of the Tender Inviting Authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause No.14.11 and 13.4.

# **19.DEDUCTION & OTHER PENALTIES ON ACCOUNT OF QUALITYFAILURE:**

19.1. If the samples do not conform to statutory standards, the Tenderer will be liable for relevant action under the existing laws and the entire stock in such batch has to be taken back by the Tenderer within a period of 30 days of the issue of the letter from the APMSIDC Such stock shall be taken back at the expense of the Tenderer. Further, actual testing charges (including handling charges for conducting those tests) shall be paid to APMSIDC by the supplier otherwise these charges shall be recovered from their pending bill/EMD/performance security deposit. The APMSIDC has the right to destroy such "NOT OFSTANDARD QUALITY DRUGS" if the Tenderer does not take back the goods within the stipulated time. The APMSIDC will arrange to destroy the "NOT OF STANDARD QUALITY DRUGS" after the expiry of 30 days mentioned above without further notice and shall also collect demurrage charges calculated at the rate of 2% per week on the value of those drugs which are of “NOT OF STANDARD QUALITY” rejected till such time stipulated. Further, the cost of disposal shall be recovered from the supplier.

**19.2.** If any items of Drugs/Medicines supplied by the Tenderer have been partially or wholly used or consumed after supply and are subsequently found to be in bad odour, unsound, inferior in quality or description(Adulterated/Spurious/Misbranded) or otherwise faulty or unfit for consumption, then the contract price or prices of total such batches supplied will be recovered from the Tenderer, if payment had already been made to him. In other words, the Tenderer will not be entitled to any payment whatsoever for Items of drugs found to be of "NOT OF STANDARD QUALITY" whether consumed or not consumed and the Tender Inviting Authority is entitled to deduct the cost of such batch of drugs from any amount payable to the Tenderer. On the basis of the nature of failure, action will be initiated to blacklist the product/supplier.

**19.3.** The Tenderer shall furnish the source of procurement of raw material utilized in the formulations, if required by the APMSIDC. The APMSIDC reserves the right to cancel the purchase orders, if the source of supply is not furnished.

**19.4.** The decision of the APMSIDC or any officer authorized by him, as to the quality of the supplied drugs, medicines etc., shall be final and binding. In such cases, the APMSIDC will be at liberty to terminate, the contract either wholly or in part on 30 days' notice. The Tenderer will not be entitled for any compensation whatsoever in respect of such termination besides forfeiture of Performance Security Deposit.

**19.5.** For contravention of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the APMSIDC, and the Tenderer shall be liable to pay for all losses sustained by the APMSIDC in consequence of the termination which may be recovered from the Tenderer, as per rules besides forfeiture of Performance Security Deposit.

**19.6.** Non-performance of any of the contract conditions and provisions will disqualify a firm from participating in the tender for the next 2 years besides forfeiture of Performance Security Deposit.

**19.7.** In the event of making Alternative Purchase, as specified in Clause 12.4 (a), Clause 14.11 and in Clause 15.3 penalty will be imposed on the supplier. The excess expenditure over and above contracted prices incurred by the APMSIDC in making such purchases from any other sources or in the open market or from any other Tenderer who has quoted higher rates and other losses sustained in the process, shall be recovered from the Performance Security Deposit or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier as per rules.

**19.8.** In all the above conditions, the decision of the MD, APMSIDC shall be final and binding.

# **20. BLACKLISTING CRITERIA**

## **20.1. BLACKLISTING OF PRODUCT/TENDERER ON WITHDRAWAL OF TENDER**

(a) If the Tenderer(s) fails to perform the obligations under the tender conditions / commits default in the performance of the contract, such Tenderers will be blacklisted for a period of 2 years by APMSIDC from the date of observing the defect besides forfeiture of Performance security deposit.

## **20.2. BLACKLISTING FOR QUALITY FAILURE**

20.2.1. Quality Test by the Empanelled Laboratories of APMSIDC

1. Each batch of drugs/medicines shall be subjected to quality test by the empanelledlaboratories.
2. The samples collected from each batch of supply of each drug will be sent to theempanelled testing laboratories for testing the quality of drugs. In addition to the above APMSIDCshall also draw the samples of products supplied to the health facilities and get the same tested, to make sure the products are conforming to quality requirements.
3. If sample passes quality tests in all respects, APMSIDC will instruct its CDS to release such items of drugs.
4. If the sample of any batch fails in quality test and report is received stating Not of Standard Quality such batch of drugs shall be rejected.
5. If the supplier challenges and requests for retesting after an NSQ is received from empanelled laboratory (other than Government Laboratory), the other portion of the same batch shall be sent to State Drugs Control Laboratory, AP or any other Government testing laboratory or NABL accredited laboratory as decided by APMSIDC. The test report received from any of these laboratories (second opinion) will be final for any decision and will be binding to the supplier. The cost of such retesting shall be recovered from the supplier.

If one/ two batches of item/drug supplied by the same supplier is reported to be NOT OFSTANDARD QUALITY (NSQ) in specifications as given in table under clause 20.2.2(b), then the product of the firm shall be blacklisted for 2 years after observing procedure laid down in Para 20.2.3.

20.2.2 Quality Test by Statutory Authorities:

1. If any drug is declared "NOT OF STANDARD QUALITY", by any of the Government testing laboratory (DCL, AP or CDTLs or NIB, Noida or any other Government labs), the issue of available stock of the particular item will be stopped. Further, the available stock of the product in hospitals/CDS will be retrieved.

|  |  |  |  |
| --- | --- | --- | --- |
| **S. No**  **(A)** | **Formulation**  **(B)** | **Test Parameters in which sample fails**  **(C)** | **No. of Batches that fail the test**  **(D)** |
| 1 | Tablets/Capsules or Other formulations | Assay for Active Pharmaceutical ingredients or Dissolution test | 02 |
| 2 | Liquid preparations | Showing Presence of Fungus, Foreign matter, Non-Dispersible Lump or Cake formation | 01 |
| 3 | Parenteral preparations | Failing in Test for Sterility, Test for Pyrogen / Endotoxin or undue Toxicity | 01 |
| 4 | Sera / Vaccines | Failing in Test for Sterility, Toxicity, Moisture Content | 01 |
| 5 | Ophthalmic preparation | Failing in test for Sterility, Fungal Growth, Foreign Matter | 01 |
| 6 | Powders | Fungal Growth | 01 |

As per the above table if number of batches of same drug (shown in column D) of a particular firm are declared as NSQ in tests shown in above table then that particular drug of the firm will be blacklisted against the firm for a period of 2 years. In case the supplier challenges the statutory test report as defined in the Drugs and Cosmetics Act, 1940 and Rules made there under 1945, issued by any Government Analyst then the test report issued by Central Drugs Laboratory, Kolkata shall be treated as final.

1. In case of other parameters (excluding those given in above table), if 3 batches are declared as NSQ then the item of the firm will be blacklisted against the firm for 2 years.
2. The amount of the NSQ batch shall be deducted/ withheld from the amount payable to the firm or from the performance security deposit of the firm. No purchase orders will be placed for the blacklisted item of the firm.
3. In case a firm is supplying more than one product and one of the products is declared as NSQ, in such case, in addition to the measure suggested above, 10% of total bill amount submitted by the firm will be withheld for a period of four months and will be paid after monitoring satisfactory supply of all other products.
4. If two items of any firm are blacklisted, then the entire firm will be blacklisted, and it will not be allowed to participate in tender for 2 consecutive years from the date of blacklisting
5. If any batch of any product(s) supplied by the company/firm declared, NOT OF STANDARD QUALITY in specification by the Government Authorities during the relevant tender period or during quality check within shelf life period, suitable action will be taken for blacklisting of the product/ firm.

20.2.3 Procedure for Blacklisting:

(i) On receipt of complaint from CDS or report from Govt. Analyst/Drug Testing Laboratory indicating that a particular Item/Drug is "NOT OF STANDARD QUALITY/ ADULTERATED/ SPURIOUS/ MISBRANDED" (As the case may be), a show cause notice shall be issued to the supplier calling for explanation within 7 days from the date of notice. On receipt of explanation from the supplier, the MD, APMSIDC may take appropriate action on merits of the case and impose penalty including the blacklisting of the item of the product/company or firm as deemed fit besides forfeiture of Performance Security Deposit.

(ii)If a particular drug has been blacklisted according to the procedure stated above, the supplier is not eligible to participate in any of the tenders for that particular item floated by the APMSIDC until the period of blacklisting is over.

(iii)If a supplier company/firm is blacklisted according to the procedure stated above, such supplier is not eligible to participate in any of the tenders floated by the APMSIDC until the period ofblacklisting is over.

## **20.3 BLACKLISTING FOR NON-SUPPLY**

Due to non-supply of item against any purchase order, 5 % value of purchase order shall be recovered from the supplier in addition of other penal like risk purchase. In case of repeated circumstances of non-supply of items i.e. 3times, the supplier may be blacklisted for 2 years in addition of forfeiture of Performance Security Deposit/ EMD and other penal action.

**20.4.** For the supply of Adulterated/Spurious/Misbranded, as defined in the Drugs and Cosmetics Act, 1940, to APMSIDC, APMSIDC reserves the right to blacklist the supplier. No further supplies shall be accepted from the firm/company. If the tenderer is blacklisted, the tenderer shall also not be eligible to participate in tenders of Tender Inviting Authority of APMSIDC for supply of Drugs for a period of 2 years from the date of blacklisting. In case of supply of NOTOF STANDARD QUALITY drug(s) to APMSIDC, the product shall be blacklisted by APMSIDC and no further supplies shall be accepted for the particular drug(s). The Tenderer shall also not be eligible to participate in tenders of APMSIDC for supply of such Drugs for a period of 2 years from the date of blacklisting. In addition, the Director of Drugs Control of concerned State will be informed for initiating necessary action on the Tenderer in their state. Performance security deposit will also be forfeited without any intimation.

## **20.5 APPEAL (s) IN CASE OF BLACKLISTING:**

1. A supplier/firm whose product or the supplier/firm, itself have been blacklisted by the corporation which is displayed in the corporation website i.e.://msidc.ap.nic.in// may within 15 days from the date of display, may appeal to the Director General, Drug Control Administration, A.P.

The Director General, Drug Control Administration, A.P., after such enquiry into the matter, as is considered necessary and after giving the said supplier an opportunity for representing his views, may pass such order in relation thereto, as he thinks fit.

1. If the firm is not satisfied with the outcome may appeal within 15 days to the Principle Secretary, Health, Medical & Family Welfare, A.P. for review. The State Government after such enquiry into the matter, as is considered necessary and after giving the said supplier an opportunity for representing his views, may pass such order in relation thereto, as it thinks fit.

# **21.SAVING CLAUSE**

No suit, prosecution or any legal proceedings shall lie against the Tender Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of the tender.

APMSIDC reserves the right to make modification, alteration or relaxation in any of the clauses or conditions given in this tender document.

# **22.RESOLUTION OF DISPUTES**

The APMSIDC and the supplier shall make every effort to resolve, amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the contract.

# **23. FRAUDULENT AND CORRUPT PRACTICES:**

(1) For bidders:

If the APMSIDC determines that a Supplier has engaged in corrupt, fraudulent, collusive, coercive or obstructive practices, in competing for or in executing the Contract, then the APMSIDC may, after giving 7 days’ notice to the Supplier, terminate the Supplier's engagement under the Contract and cancel the contract, and the procurement will be made at the risk and cost of the supplier besides blacklisting the bidder for 2 years with forfeiture of Performance security deposit apart from other penal actions.

It is purchaser's policy to ensure that suppliers and their authorized representatives/agents observe the highest standard of ethics during the procurement and execution of such contracts. (In this context, any action taken by a bidder, supplier, contractor, or by their authorized representatives/agent, to influence the procurement process or contract execution for undue advantage is improper) In pursuance of this policy, the purchaser;

1. defines, for the purposes of this provision, the terms set forth below as follows:
2. "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party ("another party" refers to a public official acting in relation to the procurement process or contract execution]. In this context, "public official" includes staff and employees of other organizations taking or reviewing procurement decisions.
3. "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation (a "party" refers to a public official; the terms "benefit" and “obligation" relate to the procurement process or contract execution; and the "act or omission “is intended to influence the procurement process or contract execution).
4. "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party ["parties “refers to participants in the procurement process (including public officials) attempting to establish bid prices at artificial, noncompetitive level].
5. "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party (a “party" refers to a participant in the procurement process or contract execution).
6. "obstructive practice" is

(a) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede an investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or acts intended to materially impede the exercise of the purchaser's inspection and audit rights provided for under sub-clause (e) below.

(b) will reject a proposal for award if it determines that the bidder considered for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for the contract in question;

(c) will cancel the contract if the purchaser determines at any time that the bidder, supplier and contractors and their sub-contractors engaged in corrupt, fraudulent, collusive, or coercive practices.

(d) will sanction a firm or individual, including declaring in eligible, either indefinitely or for a stated period of time, to be awarded a contract if it at any time determines that the firm has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for, or in executing, a contract; and

(e) will have the right to inspect the accounts and records of the bidders, supplier, and contractors and their subcontractors/authorized representatives and to have them audited by auditors appointed by the purchaser.

# **24. JURISDICTION**

In the event of any dispute arising out of the tender such dispute would subject to the jurisdiction of the Honorable Civil Courts within the city of Vijayawada only.

# ANNEXURE -I

DESIGN FOR LOGOGRAMS

TABLET CAPSULE

A

P

A P

A

P

A

P

**DESIGN FOR STRIP**

REAR SIDE

MANUFACTURED BY

MFG. LICENCSE NO:

BATCH NO:

DATE OF MANUFACTURE:

DATE OF EXPIRY:

SCHEDULE

***NOTE****:*

BRAND NAME OF THE DRUG SHOULD NOT BE PRINTED

ANY WHERE for indigenous products

Imported medicines accepted in brand name



**INJECTIONS**

Injection in ampoule form should be supplied in Double constructed neck ampoules with the label bearing the words “Andhra Pradesh Govt. Supply – Not for sale” over printed and letter containing the logogram No. 1. Which will distinguish them from the normal rate packing.

ANDHRA PRADESH GOVT.

SUPPLY NOT FOR SALE

A P

Logogram No.1

The vials should be supplied with aluminium seals containing the logogram.

ANDHRA PRADESH GOVT.

SUPPLY NOT FOR SALE

A P

In addition to the label bearing the logogram Andhra Pradesh Govt. Supply – Not for sale and the logogram No.1

**LIQUIDS**

Liquid preparations either be in HDPE bottles/ glass bottles depending on the nature of the product with pilfer-proof caps bearing the logograms:

ANDHRA PRADESH GOVT.

SUPPLY NOT FOR SALE

A P

On the top of the cap and the label to be affixed on the containers should bear a distinct colour different from the colour of the label of the trade packs and they should be over printed in red colour with the words Andhra Pradesh Government Supply -Not For Sale and the logogram above.

**Top of the cap**



ANDHRA PRADESH GOVT.

SUPPLY NOT FOR SALE

A P

Or

**SPECIMEN LABEL FOR OUTER CARTON**

**A.P. GOVT.**

**SUPPLY**

**NOT FOR SALE**

(or)

****

**DECLARATION**

I do hereby declare that I will supply the drugs and medicines as per the above design.

Signature

# **ANNEXURE -II**

(On nonjudicial Stamp Paper)

Ref. Clause No. 4.1(a)

DECLARATION

I/We M/s represented by its Proprietor/Managing Partner /Managing Director having its registered office at and its factory premises at …… do hereby declare as under: -

1. that I/we have carefully read all the terms and conditions of tender in ref. no. 60(20-21)/APMSIDC/Medicine Wing/2020-22, Dated: 03.06.2020including Amendment(s) to Tender document (if any) issued by APMSIDC, Mangalagiri and accept unconditionally all terms and condition of tender document including Amendment(s) to Tender document (if any).
2. I/We hereby declare that all required annexures and documents are uploaded.
3. Iam / We are aware of the Tender inviting Authority's right to forfeit the Earnest Money Deposit and /or Performance security deposit and blacklist me/us for a period of 2 years if, any information furnished by us proved to be false at time the of inspection and also not complying with any of the tender conditions.

Name of the bidder:

Address:

Name of the authorized signatory:

Sign and Seal:

# **ANNEXURE-III**

Ref. Clause No. 3(ii, 4.1(b) & 7.1

DETAILS OF E.M.D SUBMITTED

UPLOAD THE SCANNED COPY OF DRAFT/ PAY ORDER/BANK GURANTEE

# **ANNEXURE- IV**

Ref. Clause No.4.1(b)

{Format for a certificate from the C.A. (Chartered Accountant) or Company Secretary}

(I) It is certified that M/s is a Private. /Ltd./Proprietorship/Partnership company/firm and they have PAN no andGST registration no…. They have filed Income tax returns and GST returns up to date. The authorized signatory of the company/firm is Shri and whose signature is attested asunder:

(II) The annual Turnover of M/s for the past three years are given below and certified that the statement is true and correct.

|  |  |  |  |
| --- | --- | --- | --- |
| S. No | Financial Year | Turnover in Lakhs (Rs.) | |
| 1 | 2016-17 |  | |
| 2. | 2017-18 |  | |
| 3. | 2018-19 |  | |
| TOTAL | | Rs | ...Lakh |
| Average Turnover per annual | | Rs | ...Lakh |

1. It is certified that M/S (Name of company and address) having factory at (address of factory)have invested Rs 10 crores or above for installation of plant and machinery excluding cost towards land, building & other infrastructure to manufacture the drugs. It is also certified that the statement is true and correct.
2. It is certified that M/s has Production &financial capacity to manufacture and deliver the drugs quoted by them in the tender as per quantity & delivery schedule mentioned in tender. This certificate is based on their Manufacturing capacity, inventory of raw Material and financial statement.

Or (ONLY in case of IMPORTER)It is certified that M/s……. has Financial capacity to manufacture and deliver the drugs quoted by them in the tender as per quantity &delivery schedule mentioned in tender. This certificate is based on their Manufacturing capacity, inventory of raw Material and financial statement.

(V)Further, It is certified that M/S \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_is Micro and Small Enterprises (MSE)/SSI and registered with Director of Industries of concerned State/UT or appropriate authorities for quoted drugs against Tender : 60(20-21)/APMSIDC/Medicine Wing/2020-22, Dated: 03.06.2020 and eligible for exemption of paying EMD

Date\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(Name, Signature & Stamp)

Registration no.

# **ANNEXURE- V**

(Ref. Clause 4.1 (p)

CHECK-LIST (Whether Uploaded the documents)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| S. No. | Check List | YES | NO | PAGE |
| 1 | Processing Fee: The bidder shall remit processing fee **Rs. 5625/-** in the form of DDin the name of The Managing Director, APMSIDC, Mangalagiri. |  |  |  |
| 2 | EMD Rs. 300,000/- in the form of Bank Guarantee or Bankers Cheque or Demand Draft uploaded as per ANNEXURE-III DD No Dated issued by  (name of bank) and delivered to APMSIDC.  Uploaded NSIC or MSMEcertificate for exemption if any. |  |  |  |
| 3 | Scanned copy of Valid GMP/WHO-GMP (World Health Organization-Good Manufacturing Practices) Certificate of manufacturing company. In case of imported drugs, scanned copy Valid WHO-GMP (World Health Organization-Good Manufacturing Practices) Certificate of manufacturing company of foreign company. |  |  |  |
| 4 | Scanned copy of Valid License for the Product duly approved by the Licensing Authority for each and every product quoted.  Note : Authorization from concerned state authority for retention/renewal of the products to be furnished. |  |  |  |
| 5 | Scanned copy of Valid Import License, if Imported and wholesale Drug license |  |  |  |
| 6 | Scanned copy of Non-Conviction Certificate issued by the licensing authority not older than 6 months. |  |  |  |
| 7 | Valid COPP certificate as per WHO format of their Principal Manufacturing company including Imported drugs, if any. |  |  |  |
| 8 | Copies of approval of Manufacturing Unit of the any agency like US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa, if any. |  |  |  |
| 9 | Scanned copies of the specifications for all quoted drugs and STP (standard testing procedure) for Non- Pharmacopoeia quoted drugs. |  |  |  |
| 10 | Scanned copy of long-term stability data for all quoted drugs. If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be uploaded along with licensing agreement. |  |  |  |
| 11 | Authorization letter nominating a responsible Person of the tenderer to transact the business with the Tender inviting Authority. |  |  |  |
| 12 | Scanned copy of ANNEXURE -II (Declaration for eligibility in participating the tender**)** original Annexure II delivered to APMSIDC. |  |  |  |
| 13 | Scanned copy of ANNEXURE IV {certificate from the C.A. (Chartered Accountant) or Company Secretary. |  |  |  |
| 14 | Scanned copy of ANNEXURE-VIII  (Details for Shelf life, Manufacturing Capacity & Batch Size) with manufacturing Unit Address |  |  |  |
| 15 | Scanned copy of ANNEXURE—XIII (Mandate form) |  |  |  |

NOTE: -EMD instrument and ANNEXURE II are to be delivered in original to APMSIDC, Mangalagiri on or before Bid opening date.

Name and signature of authorized signatory

(with company seal).

# **ANNEXURE -VI**

(Ref: -Clause 7.1)

MODEL BANK GUARANTEE FORMAT FOR FURNISHING EMD

Whereas (hereinafter called the

"tenderer") has submitted their offer dated for the

supply Of Drugs (hereinafter called the "tender") against the purchaser's tender enquiry No. 50/Drugs wing KNOW ALL MEN by these presents that WE

of having our registered office at

are bound unto APMSIDC Mangalagiri (hereinafter called the "Purchaser) in the sum of Rs. One lakh only for which payment will and truly to be made to the said Purchaser, the Bank binds itself,  
its successors and assigns by these presents. Sealed with the Common Seal of the said Bank  
this day of 201.

THE CONDITIONS OF THIS OBLIGATION ARE:

1. If the tenderer withdraws or amends, impairs or derogates from the tender in any respect within the period of validity of this tender.
2. If the tenderer having been notified of the acceptance of his tender by the Purchaser during the period of its validity: -

a) If the tenderer fails to furnish the Performance Security for the due performance of the contract.

b) Fails or refuses to accept/execute the contract.

WE undertake to pay the Purchaser up to the above amount upon receipt of its first written demand, without the Purchaser having to substantiate its demand, provided that in its demand the Purchaser will note that the amount claimed by it is due to it owing to the occurrence of one or both the two conditions, specifying the occurred condition or conditions.

This guarantee will remain in force up to 06.10-2020 and any demand in respect thereof should reach the Bank not later than the above date.

(Signature of the authorized officer of the Bank)

Name and designation of the officer

Seal, name & address of the Bank

# **ANNEXURE -VII**

Ref. Clause no 13

DECLARATION

I/We do hereby declare that I/we will supply the drug as per the design in enclosures to this Annexure as well as other instruction given in this regard.

Signature of the Tenderer Name

Designation (Company Seal)

**ANNEXURE VIII provided at end of Tender document**

# ANNEXURE IX

**DECLARATION FORM**

I/We\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_having our\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Office at\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_. The conditions of tender sent to me / us by the Managing Director, Andhra Pradesh Medical Services & Infrastructure Development Corporation, Mangalagiri for the tenders floated by him for the supply of drugs, medicines etc., for the tender for a period of two years from the date of acceptance and a Tender by all conditions set forth therein.

We hereby accept to supply the drugs at the accepted \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (price) rates quoted by us in the tender document against the selected item or any matching price of Drugs Price Control Order (DPCO) as accepted by the department.

We will not quote & supply the drugs to the any agency / state in the country at the rate lower than the rate quoted in this tender.

If we quote lower rate than the rate quoted to the APMSIDC to any other agency / state in the country in future, we will remit the differential cost to the APMSIDC.

I / We further declare that I / We possess valid Drug License bearing No.

valid up to

Signature :

Date :

Name of the

Firm and address :

# ANNEXURE -X

**STATEMENT OF CAPACITY OF PRODUCTION**

1. Name of the firm:

**Manufacturing Unit Address:**

Telephone

Telex

The installed capacity of this firm is as follows per shift

Tablets Vials

Capsules Dry syrups

------------------------------------------------------

Internal

(Liquids And colloids)

Syrups Ampoules

External

Liquids

|  |  |  |  |
| --- | --- | --- | --- |
| S. No | Drug Code | Name of the drug | Maximum Shelf life in months |
| 1 |  |  |  |
| 2 |  |  |  |

Signature of the tenderer: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date \_\_\_\_\_\_\_\_\_\_\_\_\_

Full Name (IN BLOCK LETTERS) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

NOTE: - Details are to be provided for two month’s production capacity

Signature and seal of the Tenderer\_\_\_\_\_\_\_\_\_\_\_\_\_

# **ANNEXURE - X1 (A)**

Ref. Clause No. 13

UNDERTAKING

I / we do hereby declare that I/we will supply the drugs by affixing logo on Primary/Secondary/ Tertiary packing for the imported items along with the generic name as per the designs given in enclosures to this annexure as well as other instructions given in this regard.

Signature of the Tenderer

(Name in capital letter with designation)

## **Enclosure-1 to ANNEXURE - X1 AND X1 (A)**

Ref. Clause No. 13

DESIGN FOR: Foil / blister of tablet and capsule

1.Text Matter Printing on **Foil /Blister should be in minimum two colour i.e. Black & red.** However, colour and design of APMSIDC logogram in standard colour format &APMSIDC Drug code-XXXX as given in PO as per approval at the time of ARTWORK approval before supply should be as given below.

1. AP Logogram should be placed along with “AP GOVT NOT FOR SALE”.
2. Font type should in CALIBIRI format for any type of title name of generic medicines.
3. Title name of generic medicine should be bold in minimum 12 font size & the strength corresponding to it must be bold in minimum 14 font size and it may increase respectively according to size of label & the rest text matter should be in minimum 8 font size.
4. The stereo printing of batch no./manufacturing /expiry date & other details shouldn't overlap the text matter.

# **ANNEXURE-XII**

Ref. Clause No.14.1 SCHEDULE FOR PACKAGING OF DRUGS

1. **SCHEDULE FOR PACKING OF General DRUGS & I.V. FLUIDS**

**GENERAL SPECIFICATION:**

1. No corrugated package should weight more than 15 kgs (i.e. Product + inner carton + corrugated box). Except in the following cases:

1. Glutaraldehyde Solution
2. Conc. Haemodialysis Fluid
3. All Corrugated boxes should be of ‘A’ grade paper i.e., Virgin.
4. All items should be packed only in first-hand box only.

FLUTE:

1. The corrugated boxes should be of narrow flute.

JOINT:

5) Every box should be preferably single joint and not more than two joints.

STITCHING:

6) Every box should be stitched using pairs of metal pins with an interval of two inches between each pair. The boxes should be stitched and not jointed using calico at the corners.

FLAP:

7)The flaps should uniformly meet but should not overlap each other. The flap when turned by 45-60o should not crack.

TAPE:

8)Every box should be sealed with gum tape running along the top and lower opening

CARRY STRAP:

1. Every box should be strapped with two parallel nylon carry straps. (They should not intersect).

LABEL:

1. Every corrugated box should carry a large label clearly indicating that the product is for “A.P. Govt. Supply – Not for Sale”. The lower one third of the large label will indicate in bold the value of the product as depicted in Annexure III of this document.
2. The product label on the carton should be large at least 15 CMS x 10 CMS dimension. It should carry the correct technical name, strength or the product, date of manufacturing, date of expiry, quantity packed and net weight of the box.

OTHERS:

1. No box should contain mixed products or mixed batches of the same product.
2. Every consignment of blood and blood related products should be certified as
3. AIDS Free
4. Hepatitis B Free

Strips of **aluminium foils** refer to gauge 04.

**Aluminium foils** as back material for blisters refer to gauge 025.

All hygroscopic drugs and sugar-coated tablets should be stripped in aluminium foil.

The rigid PVC used in blister packing should be of not less than 250 microns.

All glass bottles should be new, neutral glass and of USP type I glass.

I.V. Fluids bottles should be fitted with nipple caps.

Small tablets packed in blisters should be so packed to facilitate removal of the tablet without breaking / crushing.

Specifications of outer cartons are as given in the schedule. (annexure VII)

In case of any conflict between carton specifications and packets per carton specifications (Last column of this table), the specification of the carton / annexure VIII shall prevail.

All tablets should have score line.

All liquid orals should be provided with a measuring device

All plastic containers should be made of virgin grade plastic of HDPE/LDPE.

All plastic jars above 450 gms/ml should carry an inner plastic lid and should be of HDPE.

**II SPECIFICATION FOR CORRUGATED BOXES HOLDING TABLETS/CAPSULES/PESSARIES**

The box should not weigh more than 7-8 kgs. The grammage should be 120-150 gsm (outer paper should be 150 gsm and others may be 120 gsm).

The box should be of 5 ply with Bursting strength of 9 kg/Cm2

**III SPECIFICATION FOR IV FLUIDS**

Each corrugated box may carry a maximum of 50 bottles of 100 ml in 2 rows with individual sealed polythene cover center partition pad, top and bottom pads of 3 ply.

2) Grammage : 120-150 Gsm (outer paper 150 gsm;

Others may be 120 gsm).

3) Ply : 5 or 7 ply.

4) Bursting Strength : Not less than 12 Kg/Cm2

IV SPECIFICATION FOR LIQUID ORALS: 50 ml to 120 ml bottles.

1. 100 bottles of 50 ml or 60 ml may be packed in a single corrugated in 2 rows with top, bottom and center pad of 3 ply.

50 bottles of 100 ml – 120 ml may be packed in a similar manner in a single corrugated box.

1. If the bottles are not packed in individual carton, 3 ply partition should be provided between each bottle. The measuring device should be packed individually.

3) Grammage : 120 – 150 Gsm (outer paper 150 gsm;

others may be 120 gsm)

4) Ply : 7 Ply

5) Bursting Strength : Not less than 12Kg/Cm2.

1. In case the box is heavier than 7 kg but less than 10 kg, the grammage may be 150gsm (outer paper 150gsm; others may be 120 gsm) 5 Ply and bursting strength should not be less than 9kg /Cm2.

V. SPECIFICATION FOR INJECTABLES (IN VIALS)

1) Vials may be packed in corrugated boxes weighing up to 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 Kgs.

2) CB for vials should be of 150 Gsm (outer paper 150 Gsm; others be 120 Gsm) and 3 ply, while CB for ampoules should be of 150 Gsm (outer 150 Gsm; others may be 120 Gsm) and 5 ply.

3) Bursting strength for CB boxes for

a) Vails : Not less than 12 Kg/Cm2

b)Amp : Not less than 9 Kg/Cm2

4) In the case of 10ml Ampoules 100 or 50 Ampoules may be

packed in a Grey board box. Multiples of grey board boxes packed in CB. In case of ampoules larger than 10 ml only 25 ampoules may be packed in a Grey board box with partition.

5) If the vials are packed in individual carton, there is no necessity for grey board box packing. The individual carton may be packed as such in the CB with center pad.

6) In case of ampoules every grey board box should carry 5 ampoule Cutters and to be placed in a polythene bag.

1. Eye and ear drop Vials has to be packed in plastic bottles of HDPE/LDPE with HDPE cap and should be packed in an individual carton and they should be packed in 50's in a Grey board box.
2. **SPECIFICATIONS FOR OINTMENT / CREAM / GELS PACKED IN TUBES:**
3. No corrugated box should weigh more than 7-9 kgs.
4. Every Ointment tube should be individually packed in a carton and then packed in 20’s in a Grey board box, which may be packed in a corrugated box.

3) Grammage : 120-150 gsm (outer paper 150 gsm; others may be 120 gsm).

4) Ply : 5

5) Bursting Strength : Not less than 9 Kg/Cm2

**VII. SPECIFICATIONS FOR ORS**

1) THE SACHETS SHOULD BE OF Aluminium foil laminated with glassine or heat sealable plastic film; outer paper may contain label information.

2) 50 sachets may be packed in grey board boxes and 10 grey board boxes in a CB.

3) grammage : 120-150 gsm (outer paper 150 gsm; others may be 120 gsm)

4) Ply : 5

5) Bursting strength : Not less than 9 Kg/Cm2

# **ANNEXURE –XIII**

MANDATE FORM

Ref. clause 16.2

| S.No. | Details Required |  |  |
| --- | --- | --- | --- |
| 1. | Company Name |  |  |
|  | PAN Number |  |  |
|  | TIN Number |  |  |
|  | GST NO. |  |  |
|  | Date of Inception |  |  |
|  | License No. & Date |  |  |
|  | Issued By |  |  |
|  | Valid Up to |  |  |
| 2. | Postal Address of the Company |  |  |
|  | Telephone No. |  |  |
|  | Fax No. |  |  |
|  | E-mail ID |  |  |
|  | Alternate E-mail ID |  |  |
| 3. | Name of the Managing Director / Director / Manager |  |  |
|  | Mobile No. / Phone No |  |  |
|  | E-mail ID |  |  |
| 4. | Name and Designation of the | Name: |  |
|  | authorized company official | Designation: |  |
|  | Mobile No. |  |  |
|  | E-mail ID |  |  |
| 5. | Bank Details | |  |
| a) Name of the Bank |  |  |
| b) Branch Name & address |  |  |
| c) Branch Code No. |  |  |
| d) Branch Manager Mobile No. |  |  |
| e) Branch Telephone no |  |  |
| f) Branch E-mail ID |  |  |
| g) 9-digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank Branch |  |  |
| h) Type of Account (Current / Savings) |  |  |
| i)Account Number (as appear in cheque book) |  |  |
| **6** | **MANUFACTURING UNIT ADDRESS** |  |  |
|  | UNIT 1 Details |  |  |
|  |  |  |  |
|  |  |  |  |
|  | UNIT 2 Details |  |  |
|  |  |  |  |
|  | ….. |  |  |
|  |  |  |  |
|  |  |  |  |

(In lieu of the bank certificate to be obtained, please upload the original cancelled chequeissued by your bank for verification of the above particulars).

I / We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all the reasons of incomplete or incorrect information, I would not hold APMSIDC responsible. I have read the conditions of the tender / Price agreement and agree to discharge the responsibility expected of me / from the company as a tenderer / successful tenderer.

Date: Place:

Company Seal Signature

(Name of the person signing & designation)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Signature of the authorized official of the bank

Bank Seal with address:

# ANNEXURE-XIV

**DECLARATION**

I, ..........................……………………………. S/o.................………………… aged about........... Years Resident of........................do here by affirm on oath as under.

That I am Managing Director/Director/Partner/Proprietor of M/s.....................................on whose behalf an application for grant of License to manufacture Drugs has been made to the Licensing Authority.

That I am responsible for the day to day affairs and conduct of business of M/s………………………………. for the purpose of Section 34 of the Drugs and Cosmetics Act, 1940 to which M/s.............................................................. and its Director/Partners etc., are held liable for any act of omission punishable under the Drugs and Cosmetics Act, 1940 and other enactment enforced by the Officers of Drugs Control Administration.

That in the event of any change in the constitution of the Company, I

will inform the concerned licensing authority. The following are the Directors/Partners of the Company as on date and whose Names and permanent address are given below:

Name. S/O Age Residential Addresses.

1.

2.

3.

WITNESSES WITH FULL ADDRESS:

1.

2.

I, Sri ..........................………………………………………………...do hereby declare on oath that the above contents are true to the best of my knowledge and belief and nothing has been hidden.

DEPONENT.

# **ANNEXURE–VIII**

Clause 8.1 &8.2

| Sr. No. | Item Code | Name of the Item | Description | Specification | Unit | Quantity |
| --- | --- | --- | --- | --- | --- | --- |
| 1 | 1525 | ACT Kit for (1-4 years) | per one kit | 1-4 years- Artesunate Tablets 50mg (3 tabs), Pyrimethamine IP 25mg, Sulphadoxine IP 500mg (tab) - Yellow Colour Blister. | Unit of 1 | 5000 |
| 2 | 1523 | ACT Kit for (9-14 years) | Per One Kit | 9-14 Years-Artisunate Tablets 50mg (3 tabs) plus Artisunate Tablets 100mg (3 tabs), Pyrimethamine IP 25mg, Sulphadoxine IP 500mg (2tabs) -RED COLOR Blister. | Unit of 1 | 10000 |
| 3 | 1522 | ACT Kit for Adults | Per One Kit | Adult- Artesunate Tablets 200mg (3tab),Pyrimethamine IP 37.5mg, Sulphadoxine IP 750mg (2tabs) -WHITE COLOR Blister. | Unit of 1 | 20000 |
| 4 | 2452 | Activated Charcoal Tablets IP 500mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 500mg | Unit of 100 | 100000 |
| 5 | 1731 | Acyclovir Ophthalmic Ointment I.P 3percentage 5gm tube | 1 X 25 (or) 1 X 50 | 5gm tube | Unit of 1 | 2000 |
| 6 | 2211 | Atropine Sulphate eye ointment 1percentage 3.5gm | 1 X 10 Tubes | 1 Percentage 3.5gm | Unit of 1 | 50000 |
| 7 | 2213 | Barium Sulfate Suspension 100percentage w/w 340 gms | 1 X 24 Pack | 100 Percentage w/w 340 gms | Unit of 1 | 575 |
| 8 | 1455 | Betaxolol eye Drops 0.25percentage, 5 ml | 5 X 5 OR 10 X5 FFS/BFS | 5 ml | Unit of 1 | 10000 |
| 9 | 1746 | Bupropion Hcl Tablets 150 mg USP | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 150 mg USP | Unit of 100 | 50000 |
| 10 | 6632 | CAPD (Continuous Ambulatory Peritoneal Dialysis) Solution Set 4.25percentage, 2 Litres Bag with Integrated Asymmetric Y.Set | 2 Litres bag with integrated asymmetric Y set | CAPD (Continuous Ambulatory Peritoneal Dialysis) Solution Set 4.25 Percentage, 2 Litres Bag with Integrated Asymmetric Y.Set | Unit of 1 | 2000 |
| 11 | 2232 | Carbolic Acid (Phenol) 500ml bottle | 1 X 20 Bottles Type 1 Glass | 500ml | Unit of 1 | 5000 |
| 12 | 1366 | Chlorine Tablets 0.5gm | 1000 TAB IN PLASTIC CONTAINER 0.5GM | 0.5gm | Unit of 1000 | 5000000 |
| 13 | 2242 | Cisplatin Injection IP 50 mg / 10 ml vial | 1X25 Vial | IP 50 mg / 10 ml vial | Unit of 1 | 9000 |
| 14 | 1763 | Clomifene Citrate Tablets IP 50 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 50 mg | Unit of 100 | 20000 |
| 15 | 1771 | Cyclophosphamide Injection IP vial 500mg | 10 ml Water for Injection | 500mg | Unit of 1 | 8000 |
| 16 | 1770 | Cyclophosphamide Tablets IP 50mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Pack | 50mg | Unit of 100 | 40000 |
| 17 | 1774 | Cyclosporine Capsules USP 25 mg | 10 x 10 Blister WithAluminum Foil Pack | 25mg | Unit of 100 | 15000 |
| 18 | 2260 | Dexmedetomidine 100mcg Injection | 1 X 25 Vials | 100mcg | Unit of 1 | 5000 |
| 19 | 2265 | Dicyclomine drops 10mg/ml, 20 ml Bottle | 1 X 50 Bottles | 10mg/ml, 20 ml Bottle | Unit of 1 | 30000 |
| 20 | 2274 | Doxylamine succinate Tablet 25 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 25 mg | Unit of 100 | 100000 |
| 21 | 1800 | Etoposide Capsules IP 100 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 100 mg | Unit of 100 | 500 |
| 22 | 1799 | Etoposide Injection 100 mg / 5 ml vial | 5 x 5 type-1 glass | 100 mg / 5 ml vial | Unit of 1 | 1000 |
| 23 | 2092 | Fondaparinux Sodium 2.5mg Inj | 1 X 5 X10 | 2.5 mg | Unit of 1 | 5000 |
| 24 | 1836 | Haloperidol Deconate Inj. 50mg | 2ml amp 10 x 10 / 5x10 type-1 glass | 50mg | Unit of 1 | 1500 |
| 25 | 1819 | Homatropine eye Drops IP 2percentage 5 ml | 5 X 5 | 2 Percentage 5 ml | Unit of 1 | 10000 |
| 26 | 1177 | Hydrogen Peroxide Solution IP 6percentage in 200ml | 200 ML CLEAR PLASTIC BOTTLE (HARD) X 20 | 6 Percentage IN 200ml | Unit of 1 | 300000 |
| 27 | 1824 | Ichthymol 1.5gm Glycerine upto 15ml NFL III | 5ml X 5 X 5 FFS | Ichthymol 1.5gm Glycerine upto 15ml NFL III | Unit of 1 | 2000 |
| 28 | 1843 | Isoprenaline Hcl Injection IP 200 micrograms / ml | 2ml amp 10 x 10 / 5x10 type-1 glass | 200 micrograms / ml | Unit of 1 | 20000 |
| 29 | 1844 | Isosorbide Dinitrate Tablets 20mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 20 mg | Unit of 100 | 100000 |
| 30 | 1636 | Isoxsuprine Hcl Tablets 10 mg | 10 x 1 0 or 50 x 10 blister with aluminum foil pack | 10 mg | Unit of 100 | 200000 |
| 31 | 1857 | Lignocaine Eye Drops BP 4 percentage in 5ml vial | 5ml X 5 X 5 OR 10 X5 FFS/BFS | 4 Percentage in 5ml | Unit of 1 | 5000 |
| 32 | 2329 | Lignocaine Hydrochloride Gel IP 2percentage 50 ml | 1 X 10 Vials | (Lignocaine Gel, Lidocaine Hcl Gel, Lidocaine Gel ) Strength 1 Percentage w/v and 2 Percentage w/ v | Unit of 1 | 3000 |
| 33 | 2337 | Lorazepam Tablet 2mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 2mg | Unit of 100 | 100000 |
| 34 | 1867 | Melphalan Tablets IP 5 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 5mg | Unit of 100 | 500 |
| 35 | 1870 | Mercaptopurine Tablets IP 50 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 50 mg | Unit of 100 | 2000 |
| 36 | 1873 | Methimazole Tablet 5mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 5mg | Unit of 100 | 10000 |
| 37 | 1875 | Methotrexate Injection IP 50 mg / ml in 2ml amp | 2ml amp10 X 10 TYPE-1 GLASS OR 5X 10 | 50 mg / ml in 2ml amp | Unit of 1 | 2000 |
| 38 | 1879 | Metolazone Tablets USP 5mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 5mg | Unit of 100 | 30000 |
| 39 | 1897 | Nitroglycerine (N.T.G.) Injection 5mg/ml in 5 ml | 10 x 10 / 5 x 10 Type-1 glass | 5mg/ml in 5 ml | Unit of 1 | 1500 |
| 40 | 1906 | Oxybutynin Tablets BP 2.5mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 2.5mg | Unit of 100 | 15000 |
| 41 | 1447 | Phenylephrine HCL Eye Drops USP 5percentage 5 ml | 5ml X 5 X 5 OR 10 X5 FFS/BFS | 5 Percentage 5 ml | Unit of 1 | 10000 |
| 42 | 1914 | Praziquantel Tablets IP 600 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 600 mg | Unit of 100 | 10000 |
| 43 | 1920 | Protamine Sulphate Injection IP 10 mg / ml in 5ml Ampoule | 5 ml vial x 5 x 5 type -1 glass | 10 mg / ml in 5ml ampoule | Unit of 1 | 5000 |
| 44 | 1925 | Pyridostigmine Tablets BP 60 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 60 mg | Unit of 100 | 25000 |
| 45 | 2393 | Pyridoxine HCL CR Tab. 100mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 100mg | Unit of 100 | 100000 |
| 46 | 574 | Pyridoxine Hcl Tablets IP 5 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 5 mg | Unit of 100 | 200000 |
| 47 | 1927 | Pyridoxine Tablets 10 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 10 mg | Unit of 100 | 30000 |
| 48 | 2399 | Quinine Sulphate Injection 600mg/ 2ml Ampule | 1 X 50 Amps | 600mg/ 2ml | Unit of 1 | 3000 |
| 49 | 2407 | Risperidone 0.5mg Tablet | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 0.5mg | Unit of 100 | 50000 |
| 50 | 2464 | Risperidone prolonged release 25 mg Suspension | 25 mg Suspension | 25 mg Suspension | Unit of 1 | 1000 |
| 51 | 2409 | Rocuronium Bromide Injection 10mg/ml, 2.5ml Vials | 1 X 25 Vials | 10mg/ml, 2.5ml Vials | Unit of 1 | 15000 |
| 52 | 2410 | Ropinirole ER Tablets 1 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 1 mg each film coated tab contains Ropinirole Hcl equi. To Ropinirole 1 mg | Unit of 100 | 25000 |
| 53 | 1948 | Silicon Oil Injection 1000mm 2/5 (cst) Injection 10ml Vial | 5 X 5 , TYPE-1 GLASS | 1000mm 2/5 (cst) Injection 10ml Vial | Unit of 1 | 100 |
| 54 | 2425 | Sodium Valporate Injection 500mg / 5ml Vial | 1 X 25 Vials | 500mg / 5ml Vial | Unit of 1 | 10000 |
| 55 | 2428 | Spiramycin Tablet 3.0 M.I.U | 10 X 10 Aluminium Blister Packs | 3.0 M.I.U | Unit of 100 | 2000 |
| 56 | 611 | Streptomycin Sulphate Injection IP 0.75g | Streptomycin Sulphate Injection Ip 0.75G | 0.75g | Unit of 1 | 5000 |
| 57 | 756 | Succinyl Choline Injection IP 50 mg / ml in 10ml vial | 5 x 5 , type-1 glass | 50 mg / ml in 10ml vial | Unit of 1 | 8000 |
| 58 | 1961 | Tacrolimus Capsules 5 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 5 mg | Unit of 100 | 10000 |
| 59 | 1257 | Tamoxifen Citrate Tablets IP 10 mg, | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 10 mg, | Unit of 100 | 20000 |
| 60 | 1970 | Tranexamic acid Tablets BP 250mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 250mg | Unit of 100 | 100000 |
| 61 | 678 | Trifluoperazine Tablets IP 5 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 5 mg | Unit of 100 | 200000 |
| 62 | 1974 | Vincristine Injection IP 1mg/ml in 1ml ampoule | 1ml AMP 10 X 10 OR 5 X 10 TYPE-I GLASS | 1mg/ml in 1ml ampoule | Unit of 1 | 1100 |
| 63 | 1976 | Warfarin sodium Tablets IP 3 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 3 mg | Unit of 100 | 25000 |
| 64 | 1975 | Warfarin sodium Tablets IP 5 mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 5 mg | Unit of 100 | 100000 |
| 65 | 2443 | Zuclopenthixol (Acetate / Decanoate ) Injection I.P 50 mg | 1 X 25 Vials | 50mg | Unit of 1 | 2000 |
| 66 | 1511 | Rabies Vaccine Human use (Cell Culture) IP ID ROUTE,1ml | ID ROUTE , 1ml with 5 ID Syringes | 1ml with 5 ID syringes | Unit of 1 | 400000 |
| 67 | 40.02 | Acetyl Salicylic Acid Tablets IP 150mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 150mg | 100 | 20621700 |
| 68 | 2062 | Acetyl Salicylic acid Tablets IP 75mg | 10 X 10 Or 50 X 10 Blister WithAluminum Foil Pack | 75mg | 100 | 11703000 |
| 69 | 1705 | Alprazolam Tablets IP 0.5 mg | 10 x 10 or 50x10 blister with aluminum foil pack. | 0.5 mg | 100 | 2052800 |
| 70 | 1188 | Amikacin Sulphate Injection IP 100 mg / 2 ml | 10X 10 / 5 X 10 , Type-I glass. | 100 mg / 2 ml | 1 | 1213920 |
| 71 | 8 | Amoxicillin oral suspension IP 125 mg / 5 ml in 60ml | 60ml X 100 , Glass Bottle/HDPE Bottle | 125 mg / 5 ml in 60ml | 1 | 6199950 |
| 72 | 1340 | Amoxycillin 500mg plus 125mg Potassium Clavulanic Acid Tablets IP | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 500 mg Amoxycillin plus 125 mg Potassium Clavulanate Tablets IP | 100 | 71854500 |
| 73 | 2065 | Atorvastatin Tablets IP 10mg | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | 10mg | 100 | 23516200 |
| 74 | 2212 | Atropine sulphate injection 0.6percentage, 100ml vial | 1 X 10 Vilas Type -1 Glass | 0.6 Percentage, 100ml vial | 1 | 370570 |
| 75 | 1699 | Azithromycin Dispersible Tablet 100 Mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 100 mg | 100 | 1815300 |
| 76 | 2217 | Betahistine Tablets IP 16 mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 16 mg | 100 | 2471500 |
| 77 | 2225 | Calcium Citrate 1000 mgplus Vit. D3 200 I.U. Methylcobalamin 500 mcgplus Folic Acid 5mg plus Pyridoxine Hcl 10 mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | Calcium Citrate 1000 mgplus Vit. D3 200 I.U. Methylcobalamin 500 mcgplus Folic Acid 5mg plus Pyridoxine Hcl 10 mg | 100 | 2635500 |
| 78 | 2069 | Carbmazepine Tablets 200mg | 10 x 10 or 50 x 10 blister with aluminum foil pack | 200mg | 100 | 7676500 |
| 79 | 1621 | Cefixime Dispersible Tablets USP 100 mg | 5 X10X 10 BLISTER WITH ALUMINUM FOIL PACK. | 100 mg | 100 | 16981100 |
| 80 | 2235 | Cefixime oral suspension 100mg / 5ml in 60ml Bottle | 1 X 50 Bottles | 100mg / 5ml in 60ml Bottle | 1 | 145880 |
| 81 | 2236 | Cefixime Oral Suspension 25mg/ml, 10ml Bottle | 1 X 50 Bottles | 25mg/ml, 10ml Bottle | 1 | 3118280 |
| 82 | 1625 | Chloroquine Phosphate Syrup 50 mg / 5 ml in 60ml | 60ML X 100 , AMBER COLOUR PET BOTTLE | 50 mg / 5 ml in 60ml | 1 | 476800 |
| 83 | 95 | Ciprofloxacin Injection IP 200mg/100ml BFS / FFS | 5 X 5 X 4, BFS / FFS | 200mg/100ml | 1 | 4291210 |
| 84 | 1389 | Clotrimazole Pessaries IP 100 mg | 6x 10 blister with aluminum foil pack with applicator | 100 mg | 60 | 1741300 |
| 85 | 98 | Cotrimaxazole Oral Suspension IP. 40mgplus200mg | 50ml X 50 / 100 , Amber Colour Pet Bottle | Co-trimoxazole oral suspension I.P Trimethoprim 40mg plus sulphamethoxazole 200mg/5ml in 50ml bottle | 1 | 4118910 |
| 86 | 97 | Cotrimaxazole Tabs. IP 160mgplus800mg (TrimethoprimplusSulphamethoxazole ) | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 160mg plus 800 mg | 100 | 39660400 |
| 87 | 224 | Dextrose with Sodium Chloride Injection 5percentage plus 0.9percentage IP in 500ml IV BFS / FFS | 500ML X 24 / 4 X6 PLASTIC BOTTLE BFS / FFS (SEPARATION BETWEEN EACH BOTTLE IS MUST) | 5 Percentage plus 0.9 Percentage IP in 500ml | 1 | 6218730 |
| 88 | 197 | Diclofenac Sodium 50mg Tablets IP (Enteric coated Tablets) | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 50mg | 100 | 425000000 |
| 89 | 193 | Dicyclomine Hcl Tablets 10 mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 10 mg | 100 | 46768900 |
| 90 | 201 | Diethylcarbamazine Citrate Tablets IP 100mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 100mg | 100 | 9660500 |
| 91 | 1151 | Domperidone Suspension IP 1 mg / ml in 30ml bottle | 30 ML X 100BOTTLES AMBER COLOUR PET BOTTLE | 1 mg / ml in 30ml bottle | 1 | 3488870 |
| 92 | 1137 | Domperidone Tablets IP 10 mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 10 mg | 100 | 58199500 |
| 93 | 251 | Enalapril Maleate Tablets IP 5mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 5 mg | 100 | 43552900 |
| 94 | 2281 | Escitalopram Tablets 5mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 5mg | 100 | 1046100 |
| 95 | 1462 | Ethamsylate Injection125mg/ml 2 ml ampoule | 10 x 10 (or) 5x10 type-1 glass | 125mg/ml 2 ml ampoule | 1 | 621740 |
| 96 | 211 | Etophylline 77mg plus Theophylline 23mg Tablets IP | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 77mg plus 23mg | 100 | 75448900 |
| 97 | 2287 | Ferrous ascorbate equivalent to 50 mg Iron plus Folic acid 1.5 mg) tablet | 10 X 10 or 5x10x10 Aluminum Foil Pack | 50 mg | 100 | 33390300 |
| 98 | 279 | Folic Acid Tablets 5mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 5 mg | 100 | 60875600 |
| 99 | 285 | Formaldehyde Solution 500ml bottle | 500 ml clear plastic bottle (hard) x 20 bottles in one carton | 500ml bottle | 1 | 341740 |
| 100 | 2295 | Framycetin Sulphate Cream 1percentage w/w 100gm tube | 10 X 10, 10 individual tetra pack | 1 Percentage w/w 100gm tube | 1 | 2124410 |
| 101 | 2296 | Framycetin Sulphate Cream 1percentage w/w 30gm tube | 10 X 10, 10 individual tetra pack | 1 Percentage w/w 30gm tube | 1 | 2961580 |
| 102 | 743 | Furazolidone Suspension IP 25mg/5ml,60ml | 60ml X 100 Amber Colour Pet Bottle | 25mg/5ml,60ml | 1 | 4110710 |
| 103 | 265 | Furosemide Tablets IP 40mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 40mg | 100 | 10547800 |
| 104 | 311 | Gamma Benzene Hexachloride Lotion 1percentage in 60ml bottle | 60ML CLEAR PLASTIC BOTTLE (HARD) X 100 | 1 Percentage in 60ml bottle | 1 | 2992480 |
| 105 | 2313 | Isosorbide Dinitrate Tablets 10mg | 10 X 10 or 5x10x10 Aluminum Foil Pack | 10mg | 100 | 4761300 |
| 106 | 2320 | Labetalol Hydrochloride Tablet IP 100mg | Film coated 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 100mg | 100 | 610700 |
| 107 | 2323 | Levocetirizine Syrup 2.5mg/5ml in 60ml bottle | 1 X 50 Bottles | 2.5mg/5ml in 60ml bottle | 1 | 138230 |
| 108 | 2325 | Levofloxacin Tablet 500 mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 500 mg | 100 | 7356300 |
| 109 | 2327 | Levothyroxine Tablets 25mcg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 25mcg | 100 | 849000 |
| 110 | 2111 | Levothyroxine Tablets 50mcg | 10 x 10 or 50 x 10 blister with aluminum foil pack | 50mcg | 100 | 1808700 |
| 111 | 1438 | Levothyroxine Tablets IP 100 micrograms(uncoated) | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 100 micrograms(uncoated) | 100 | 2612900 |
| 112 | 2334 | Liquid Paraffin 3.75 ml plus milk of Magnesia 11.25 ml each 15 ml contain 170 ml bottle Syrup | 1 X10 Bottles | 3.75 ml plus 11.25 ml each 15 ml contain 170 ml bottle | 1 | 154270 |
| 113 | 1865 | Mefenamic Acid Tablets BP 500 mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 500 mg | 100 | 1381400 |
| 114 | 714 | Menadione Sodium Bisulphate Inj 10mg/ml 1ml Amp USP | 1ML AMP AMBER COLOUR AMP 10 X 10 TYPE 1 GLASS | Inj 10mg/ml 1ml Amp USP | 1 | 567420 |
| 115 | 1643 | Metronidazole benzoate Oral Suspension IP 100mg/5ml in 60ml | 60 ML X 100 BOTTLES AMBER COLOUR PET BOTTLE | 100mg/5ml in 60ml | 1 | 2804570 |
| 116 | 440 | Metronidazole IV Infusion IP 500mg in 100 ml | 5 X 5 X 4 OR 100ML X4X6X4 BFS / FFS | 500mg in 100 ml | 1 | 8346740 |
| 117 | 475 | Miconazole Nitrate Cream IP 2percentage 30gm tube -Cream | 30 GM X 10X10 | 2 Percentage 30gm | 1 | 5590340 |
| 118 | 2350 | Naproxen Sodium Tablet 250mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 250mg | 100 | 254400 |
| 119 | 2351 | Naproxen Sodium Tablet 500mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 500mg | 100 | 369200 |
| 120 | 497 | Nifedipine Capsules IP 10mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 10mg | 100 | 8835800 |
| 121 | 2364 | Noradrenaline Injection 1mg/ml, 2ml ampoules | 1 X50 Amp | 1mg/ml, 2ml | 1 | 475960 |
| 122 | 482 | Norfloxacin Tablets IP 400mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 400mg | 100 | 32250300 |
| 123 | 1702 | Ofloxacin Suspension 50 mg /5 ml , 60 ml | 60 ML X 100 BOTTLES AMBER COLOUR PET BOTTLE | 50 mg /5 ml , 60 ml | 1 | 3785600 |
| 124 | 2366 | Oint.Salicylic Acid IP 12.0percentage w/w 50 gms tube | 1 X10 Tubes | 12.0 Percentage w/w 50 gms | 1 | 1637330 |
| 125 | 2367 | Oint.Salicylic Acid IP 6.0percentage w/w 30 gms tube | 1 X10 Tubes | 6.0 Percentage w/w 30 gms | 1 | 1512770 |
| 126 | 2368 | Olanzapine Tablets 2.5mg | 2.5mg , 10 x 10 milky white PVC aluminium foil pack | 2.5mg | 100 | 614400 |
| 127 | 527.01 | Paracetamol Injection 300mg in 2ml | 2ML AMP 10 X 10 / 5 X 10 TYPE-1 GLASS | 300mg in 2ml | 1 | 8645700 |
| 128 | 1701 | Paracetamol Syrup IP (Non-Alcohol based) 125 mg / 5 ml in 60ml | 60 ML X 100 BOTTLES AMBER COLOUR PET BOTTLE | 125 mg / 5 ml in 60ml | 1 | 10154400 |
| 129 | 1650 | Permethrin Cream 5percentage 30gms tube | 30 GM X 10X10 | 5 Percentage 30gms | 1 | 556980 |
| 130 | 1653 | Povidone Iodine Ointment USP IP 5percentage, 100gm | 100 GM X 10 X 10 | 5 Percentage, 100gm | 1 | 4378340 |
| 131 | 1521 | Primaquine Tablets IP 2.5 mg | 10 x 10 or 50x10 blister with aluminum foil pack | 2.5 mg | 100 | 1767300 |
| 132 | 2398 | Quetiapine 50mg Tablet | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 50mg | 100 | 1010700 |
| 133 | 1682 | Salicylic Acid Cream 5percentage , 30gms tube | 30GM X 10 X 10 ( 10 TUBES TETRA PACK) | 5 Percentage , 30gms tube | 1 | 1675350 |
| 134 | 2419 | Sertaconazole Nitrate BP 2percentage w/v Propylene Glycol base q.s. Pack -Bottle of 15 ml | 1 X25 Bottles | BP 2 Percentage w/v 15 ml | 1 | 472880 |
| 135 | 1474 | Sulfadoxine plus Pyrimethamine 500 mg Sulfadoxine plus 25 mg Pyrimethamine Tablets IP | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | Sulfadoxine plus Pyrimethamine 500 mg Sulfadoxine plus 25 mg Pyrimethamine Tablets IP | 100 | 1060600 |
| 136 | 1370 | Vitamin A Paediatric retinol solution 100000 IU per ml | Amber Coloured Glass Bottle. Individual Monopackwith 2ml Plastic Measuring Cap with Inner Marking For 1ml | 100000 IU per ml | 1 | 1690950 |
| 137 | 1454 | Xylometazoline Nasal Drops 0.1percentage w/v 10 ml | 5 X 5 | 0.1 Percentage w/v 10 ml | 1 | 1598360 |
| 138 | 2440 | Zinc Sulphate Dispersible Tablet10mg | 10X10 or 50X10 Blister with aluminum foil pack | 10mg | 100 | 12479800 |
| 139 | 1691 | Aciclovir Tablets IP 400 mg | 10 X 1 0 Or 50 X 10 Blister WithAluminum Foil Pack, Outer Carton Maximum Of 10000 | 400 mg | 100 | 1492500 |
| 140 | 2205 | Amitriptyline Tablets 25mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 25 mg | 100 | 2924300 |
| 141 | 1742 | Balanced Salt Solution Ophthalmic Solution 500 ml Pouch | 300ML MONO PACK | 500 ml Pouch | 1 | 36560 |
| 142 | 2219 | Bisacodyl Suppositories 10mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 10mg | 60 | 139400 |
| 143 | 2231 | Carbimazole Tablet 10mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 10mg | 100 | 100100 |
| 144 | 2146 | Carbimazole Tablets 20mg | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | 20mg | 100 | 210200 |
| 145 | 1145 | Carbimazole Tablets 5mg | 10 x 10 or 50 x 10 blister with aluminum foil pack | 5mg | 100 | 233000 |
| 146 | 1690 | Carbmazepine Suspension USP 100mg/5ml, in 100ml | 100 ml amber colour pet bottle x 50 | 100mg/5ml in 100ml | 1 | 30960 |
| 147 | 136 | Carbmazepine Tablets (Film coated) 100mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 100mg | 100 | 4490600 |
| 148 | 2243 | Clindamycin 1 percentage gel 30 gms | 1 X 10 Tubes | 1 Percentage gel 30 gms | 1 | 937290 |
| 149 | 1338 | Clopidogrel Bisulphate Tablets I.P. 75mg,(Film coated) | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 75mg | 100 | 12208600 |
| 150 | 2258 | Deflazacort Tablets 6mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 6mg | 100 | 940200 |
| 151 | 2080 | Diclofenac Sodium Tablets 100mg SR | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | 100mg SR | 100 | 25610900 |
| 152 | 207 | Diltiazem Tablets IP 30 mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 30 mg | 100 | 322000 |
| 153 | 1218 | Dobutamine Hcl For Injection USP 250mg / 20 ml Vial | 20ML VIAL X 5 X 5 ,TYPE-1 GLASS | 250mg / 20 ml Vial | 1 | 127920 |
| 154 | 209 | Dopamine Hcl Injection IP 200mg in 5ml vial and ampoule | 5 X5 TYPE-1 GLASS | 200mg in 5ml vial and ampoule | 1 | 280640 |
| 155 | 1791 | Drotaverine Injection 40mg/2ml in 2 ml amp | 2ML AMP 10 X 10 / 5X10 TYPE-1 GLASS | 40mg/2ml in 2 ml amp | 1 | 229490 |
| 156 | 1804 | Fentanyl Inj. 100mcg/2ml | 2ML AMP 10 X 10 / 5X10 TYPE-1 GLASS | 100mcg/2ml | 1 | 102780 |
| 157 | 2297 | Gabapentin Tablets 300mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 300mg | 100 | 1098300 |
| 158 | 1431 | Gatifloxacin eye Drops 0.3 w/v in 5ml vial | 5ML X 5 X 5, | 0.3 w/v in 5ml vial | 1 | 161750 |
| 159 | 1665 | Glycerine IP 450gm | Clear Plastic Bottle (Hard) X 20 Bottles in On Carton | 450gm | 1 | 47880 |
| 160 | 666 | Glycopyrrolate Injection 0.2 mg / ml in 1ml amp IP | 10x 10 / 1x5x10 type-1 glass | 0.2 mg / ml in 1ml amp IP | 1 | 216180 |
| 161 | 308 | Griseofulvin Tablets IP 125 mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 125 mg | 100 | 2132600 |
| 162 | 1676 | Hydroxyethyl starch BP ( Hetastarch) with 450K Dalton/Tetra starch Hydroxyethyl starch 130K Dalton molecular weight | 24 OR 4 X 6 IN ONE CARTON SPEORATION BETWEEN EACH BOTTLES IS MUST | Hydroxyethyl starch BP ( Hetastarch) with 450K Dalton/Tetra starch Hydroxyethyl starch 130K Dalton molecular weight | 1 | 63580 |
| 163 | 2316 | Itraconazole Capsule 100 mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 100 mg | 100 | 374700 |
| 164 | 2317 | Ivermectin Tablets USP 6mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 6mg | 100 | 87200 |
| 165 | 2319 | Ketorolac Tromethamine Injection 30mg /ml, 1 ml Ampoule | 1 X 50 Amps | 30mg /ml, 1 ml | 1 | 225780 |
| 166 | 1694 | Labetalol Hcl Injection IP 5mg / ml in 10ml vial | 5 X 5 / 10MLX5X10 , TYPE-1 GLASS | 5mg / ml in 10ml vial | 1 | 122130 |
| 167 | 1637 | Lactulose Solution 3.325gm/5ml in 100ml bottle | 100ML X 50 PLASTIC BOTTLE | 3.325gm/5ml in 100ml bottle | 1 | 396920 |
| 168 | 2335 | Liquid Paraffin 500ml | 1 X10 Bottles | 500ml | 1 | 75680 |
| 169 | 1162 | Loperamide Tablets 2mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 2mg | 100 | 3165600 |
| 170 | 1639 | Mannitol 20percentage I.V. Infusion IP 100ml bottle BFS/FFS | 100ML PLASTIC BOTTLE X 50 / 5 X 5 X 4 BFS / FFS | 100ml bottle BFS/FFS | 1 | 1430650 |
| 171 | 2113 | Montelukast Tab 10mg | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | 10mg | 100 | 1656900 |
| 172 | 2352 | Natural Progesterone Injection 100mg/2 ml 2ml Ampule | 1 X50 Amp | 100mg/2 ml 2ml | 1 | 222540 |
| 173 | 2353 | Nepafenac 0.1percentagew/v Eye Drops , 5ml Vial | 1X25 Vials | 0.1 Percentage/v Eye Drops , 5ml Vial | 1 | 77600 |
| 174 | 1647 | Ondansetron Syrup IP 2mg/5ml in 30 ml bottle | 30 ML X 100 AMBER COLOUR PET BOTTLE | 2mg/5ml in 30 ml bottle | 1 | 502550 |
| 175 | 2119 | Paracetamol Solution for Infusion (10mg/ml) in 100ml glass bottle i.e.1gm/100ml BFS/FFS | 1X10X10 OR 1X5X10 | 1gm/100ml | 1 | 440700 |
| 176 | 2379 | Pethidine Hydrochloride Injection BP 50mg/ ml | 1 X 50 Amps | BP 50mg/ ml | 1 | 42740 |
| 177 | 2382 | Phenytoin sodium Tablets IP 300mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 300mg | 100 | 1463300 |
| 178 | 2383 | Piperacillin plus tazobactam Injection 2gm plus0.25gm | 1 X 25 Vials | Piperacillin plus Tazobactam Injection 2gm plus0.25gm | 1 | 86780 |
| 179 | 2388 | Potassium Chloride Injection 150mg/ml,10ml Ampoule | 1 X 25 Amps | 150mg/ml,10ml | 1 | 179420 |
| 180 | 2389 | Povidone Iodine Eye Drops 5percentage, 5ml Vial | 1 X 25 Vials | 5 Percentage, 5ml Vial | 1 | 13590 |
| 181 | 577 | Prednisolone Tab 10mg | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | 10mg (Both Regular and Dispersible) | 100 | 2008400 |
| 182 | 1492 | Prednisolone Tab 20mg | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | 20mg (Both Regular and Dispersible) | 100 | 1349800 |
| 183 | 1930 | Ramipril Tablets IP 5mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 5mg | 100 | 445800 |
| 184 | 1134 | Risperidone Tablets USP 2 mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 2 mg | 100 | 9185300 |
| 185 | 2418 | Sertaconazole Nitrate (Pessaries) 500 mg Tablet | 10 X 10 Aluminium Blister Packs | 500 mg Tablet | 60 | 2008700 |
| 186 | 1254 | Spironolactone Tablets IP 25 mg, | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 25mg | 100 | 2760800 |
| 187 | 2432 | Thiamine Injection 100mg / ml vial 2 ml | 1 X 25 Vials | 100mg / ml vial 2 ml | 1 | 803460 |
| 188 | 664 | Thiopentone Sodium Injection IP 0.5gm /ml | 0.5 gm X 20 Vials with Distilled Water, Amber Colour Type 1 Glass | 0.5gm /ml | 1 | 60260 |
| 189 | 2434 | Timolol Maleate eye Drops IP 0.5percentage, 5 ml | 1 X 25 Vials | 0.5 Percentage, 5 ml | 1 | 26550 |
| 190 | 1683 | Triamcinolone acetate Injection IP 40mg/ml 1ml vial | 1ml vial 10 x 10 or 5x 10,type-1 glass | 40mg/ml 1ml vial | 1 | 71510 |
| 191 | 2437 | Trypsin and Chymotrypsin Tablets 10 mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 10 mg | 100 | 1839200 |
| 192 | 1479 | Acyclovir Injection 250mg | 5 X 10 | 250mg | 1 | 82640 |
| 193 | 1739 | Atorvastatin Tablets IP 20mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 20mg | 100 | 16214100 |
| 194 | 2238 | Chlordiazepoxide Tablets 25mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 25mg | 100 | 552800 |
| 195 | 2241 | Cilostazole Tablet 100mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 100mg | 100 | 18000 |
| 196 | 2244 | Clindamycin 1percentage w/w plus Benzoyl Peroxide 2.5 w/w 15 gms | 1 X 10 Tubes | 1 Percentage w/w plus 2.5 w/w 15 gms | 1 | 74150 |
| 197 | 2245 | Clindamycin Injection 150 mg/ml in 2ml ampoule | 1 X25 Vials | 150 mg/ml in 2ml ampoule | 1 | 107460 |
| 198 | 2250 | Coagulation Factor VIII rF VIII ( Recombinant or Freeze Dried ) 1000 IU | 1 X 10 Vials | 1000 IU | 1 | 780 |
| 199 | 2252 | Coagulation Factor VIII rF VIII (Recombinant or Freeze Dried ) 250 IU | 1 X 10 Vials | 250 IU | 1 | 4980 |
| 200 | 2251 | Coagulation Factor VIII rF VIII (Recombinant or Freeze Dried) 1500 IU | 1 X 10 Vials | 1500 IU | 1 | 780 |
| 201 | 2255 | Cyclopentolate Eye drops 1percentage 5ml | 1 X 25 Vials | 1 Percentage in 5ml | 1 | 6020 |
| 202 | 2257 | Dabigatran EtexilateMesilate Capsules 75mg | 10 X10 Aluminium Blister Pack | 75 mg | 100 | 11900 |
| 203 | 2262 | Dextrose 10percentage I.V 500 ml | 1 X 24 Bottles | 10 Percentage I.V 500 ml | 1 | 82140 |
| 204 | 2271 | Donepezil Tablets 5mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 5mg | 100 | 360900 |
| 205 | 2280 | Erythromycin Syp 60 ml ( each 5ml contains 125 mg) | 1 X 50 Bottles | 60 ml ( each 5ml contains 125 mg) | 1 | 10520 |
| 206 | 1794 | Escitalopram Tablets 10mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 10mg | 100 | 2037200 |
| 207 | 2290 | Fluocinolone Acetonide 0.01percentage w/w Lotion 30 ml | 1 X 25 Bottles | 0.01 Percentage w/w Lotion 30 ml | 1 | 42810 |
| 208 | 2289 | Fluocinolone Acetonide 0.1percentage w/w cream 30 gm | 1 X 10 Tubes | 0.1 Percentage w/w cream 30 gm | 1 | 45900 |
| 209 | 2292 | Flunarizine Tablets 10mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 10mg | 100 | 184800 |
| 210 | 2293 | Fluoxetine Capsule 20mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 20mg | 100 | 1764800 |
| 211 | 1806 | Fluphenazine Deaconate Inj. IP 25mg/ ml Depot 1 ml | 10 x 10 / 5 x 10 type-1 glass | 25mg/ ml Depot 1 ml | 1 | 16800 |
| 212 | 1377 | Flurbiprofen Eye drops BP 0.03percentage 5 ml | 5ml x 5 x 5 | 0.03 Percentage in 5 ml | 1 | 49460 |
| 213 | 1630 | Griseofulvin Tablets IP 250 mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 250 mg | 100 | 2089200 |
| 214 | 2304 | Hydroxy Propyl Methyl Cellulose Eye Drops 0.3percentage in 10 ml | 1 X 25 Vials | 0.3 Percentage in 10 ml | 1 | 50660 |
| 215 | 2310 | Indacaterol 110mcgplusGlycopyrronium 50 mcg Capsules plus inhaler | 1 X 25 Inhalers | 110mcgplus 50 mcg | 1 | 10430 |
| 216 | 1846 | Ivermectin Tablets USP 3mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 3mg | 100 | 217700 |
| 217 | 2318 | Japanese Encephalitis Vaccine, Inactivated (Absorbed, Human) IP 0.5ml vial | 1 X 10 Vials | IP 0.5ml vial | 1 | 2210 |
| 218 | 2326 | Levofloxacin Tablet 750 mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 750 mg | 100 | 3122700 |
| 219 | 2333 | Liquid Paraffin 100 ml | 1 X10 Bottles | 100 ml | 1 | 73340 |
| 220 | 2339 | Mebeverine Hydrochloride IP 135mg Tablet | 10 X 10 Blister with Aluminum Foil Pack | 135mg | 100 | 38700 |
| 221 | 1866 | Mefloquine Hcl IP Tablets 250mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 250mg | 100 | 5300 |
| 222 | 2340 | Memantine 10mg Tablet | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 10mg | 100 | 108500 |
| 223 | 1700 | Meropenem Injection IP 1gm vial | 30 ML VIAL X5X 5, TYPE-1 GLASS | 1gm Vial | 1 | 309380 |
| 224 | 2342 | Mesalazine Tablet 1.2 gm | 10 X 10 Blister with Aluminum Foil Pack | 1.2 gm | 100 | 20300 |
| 225 | 1310 | Methyl Prednisolone Sodium Succinate Injection USP 500 mg | 5ML AMBER COLOUR VIAL 5X5 OR 10X5 | 500mg | 1 | 89420 |
| 226 | 2343 | Methyl Prednisolone IP 4mg Tablet | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 4mg | 100 | 226400 |
| 227 | 2344 | Methyl Prednisolone IP 8mg Tablet | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 8mg | 100 | 209300 |
| 228 | 2345 | Metoprolol 5mg/5ml Injection Ampule | 1X50 Amp | 5mg/5ml | 1 | 7010 |
| 229 | 1888 | Mycophenolate mofetil Tab 500mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 500mg | 100 | 94500 |
| 230 | 1903 | Olanzapine Tablets 5 mg | 10 X 10 MILKY WHITE PVC ALLUMINIUM FOIL PACK | 5 mg | 100 | 2451500 |
| 231 | 1905 | Olopatadine eye drops 0.1percentagew/v | 5 ML X 5 X 5 OR 10 X5 FFS / BFS | 0.1 Percentage w/v | 1 | 34880 |
| 232 | 2375 | Paraffin Wax 500 gms | 1 X 20 Tins | 500 gms | 1 | 3160 |
| 233 | 2385 | Polyethylene glycon with electrolytes for oral solution 137.15 gms powder | 1 X 50 Sachets | 137.15 gms | 1 | 79430 |
| 234 | 2386 | Porcine Lung Surfactant 1.5 ml 120mg | 1 X 10 Respules | 1.5 ml 120mg | 1 | 1490 |
| 235 | 2387 | Porcine Lung Surfactant 3ml 240mg | 1 X 10 Respules | 3ml 240mg | 1 | 1670 |
| 236 | 2395 | Quadrivalent Human Papilloma Virus Vaccine Injection (0.5ml PFS) | 1 X 10 Vials | (0.5ml PFS) | 1 | 4520 |
| 237 | 2397 | Quetiapine 25mg Tablet | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 25mg | 100 | 430400 |
| 238 | 2411 | Ropivacaine Injection 0.75mgpercentage, 10ml Vial | 1 X 25 Vilas | 0.75mg Percentage, 10ml Vial | 1 | 24910 |
| 239 | 2412 | Rosuvastatin Calcium 20 mg Tablet | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 20 mg | 100 | 519800 |
| 240 | 2420 | Sertaconazole Nitrate BP 2percentage w/v Propylene Glycol base q.s. Pack -Tube of 15 gms | 1 X 10 Tubes | BP 2 Percentage w/v 15 gms | 1 | 79200 |
| 241 | 2423 | Sodium Chloride Eye drops 5percentage 5ml | 1 X 25 Vials | 5 Percentage 5ml | 1 | 20610 |
| 242 | 1953 | Sodium valproate Tablets IP 200mg | 10 X 10 OR 50X10 BLISTER WITH ALUMINUM FOIL PACK | 200mg | 100 | 7246100 |
| 243 | 2429 | Spironolactone Tablets IP 50 mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 50 mg | 100 | 498500 |
| 244 | 1967 | Tobramycin Eye drops 0.3percentage in 5 ml vial | 5ML X 5 X 5 | 0.3 Percentage in 5 ml vial | 1 | 48600 |
| 245 | 1908 | Trichlofos BP 500mg/5ml BP | 60ml x 50 amber colour pet bottle | 500mg/5ml BP | 1 | 3870 |
| 246 | 1372 | Tropicamide plus phenylephrine 5 ml Eye drops | 5ML X 5 X 5 | 5 ml | 1 | 58280 |
| 247 | 2163 | Verapamil Tab 40mg | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | 40mg | 100 | 99900 |
| 248 | 2164 | Verapamil Tab 80mg | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | 80mg | 100 | 109200 |
| 249 | 1225 | 5-Fluorouracil Injection IP 250 mg /5 ml in 5 ml amp | 250 MG 5 ML IN 5 ML AMP X5 X 5 TYPE I GLASS | 250 mg/5 ml in 5 ml amp | 1 | 59550 |
| 250 | 1526 | ACT Kit for (0-1 years) | Per One Kit | 0-1 years Artisunate Tablets 25mg (3 tabs), Pyrimethamine IP 6.25mg,Sulphadoxine IP125mg (1tab) - PINK COLOR Blister | 1 | 7070 |
| 251 | 1733 | Adenosine Injection IP 3mg / ml 2ml vial or ampoule | 10 x 5 ,type-1 glass | 3mg / ml 2ml vial or Ampoule | 1 | 9500 |
| 252 | 2203 | Adriamycin Injection 50mg / 25ml vial | 5 X 5 Or 10 X 5 Vial | 50mg / 25ml vial | 1 | 64810 |
| 253 | 1734 | Allopurinol Tablets IP 100 mg | 10 x 10 or 50x10 blister with aluminum foil pack. | 100 mg | 100 | 30800 |
| 254 | 2208 | Anti-Inhibitor Coagulant Complex (Intravenous Route) 500 IU vial | 1 X 10 Vilas Type -1 Glass | 500 IU vial | 1 | 410 |
| 255 | 1743 | Bleomycin for Injection 15 units IP vial(powder) | 1x5x10 | 15units IP vial(powder) | 1 | 1680 |
| 256 | 1744 | Bromocriptine Mesylate Tablets IP 2.5mg | 10 x 10 or 50 x 10 blister with aluminum foil pack | 2.5mg | 100 | 27500 |
| 257 | 2227 | Calcium Leucovorin Injection 50mg/ 5 ml vial | 1 X 25 / 1 X 50 Vials Type 1 Glass | 50mg/ 5 ml vial | 1 | 120930 |
| 258 | 2233 | Carboplatin 150mg /15 ml Injection Vial | 1 X 25 Vilas Type 1 Glass | 150mg /15 ml Vial | 1 | 2120 |
| 259 | 2234 | Carboplatin 450mg / 45 ml Injection Vial | 1 X 10 Ml Vials Type 1 Glass | 450mg / 45 ml Vial | 1 | 4430 |
| 260 | 1623 | Chloramphenicol Ear drops IP 5ml | 5ML X 5 X 5 OR 10 X5 FFS/BFS | 5ml | 1 | 35700 |
| 261 | 1267 | Cisplatin Injection IP 10 mg / 10 ml vial | 10MG/10ML AMBER COLOUR 1X50 VIAL | 10 mg / 10 ml vial | 1 | 66300 |
| 262 | 2073 | Citicoline Tab 500mg | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | 500mg | 100 | 739000 |
| 263 | 1426 | Clotrimazole Ear Drops 1percentage in 5ml vial | 5ml x 5 x 5 / 5ml x 5 x 10 | 5ml vial | 1 | 52140 |
| 264 | 2264 | Diclofenac Sodium suppositories 100 mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 100 mg | 100 | 340200 |
| 265 | 2269 | Docetaxel 20mg/5ml or 20 mg/0.5 ml fill volume in 5 ml vial | 1 X 25 Vials | 20mg/5ml or 20 mg/0.5 ml fill volume in 5 ml vial | 1 | 1060 |
| 266 | 2270 | Docetaxel 80mg/ 2 ml vial | 1 X 25 Vials | 80mg/ 2 ml vial | 1 | 1060 |
| 267 | 1220 | Doxorubicin Injection IP 10 mg / 5 ml | 5ML VIAL X 5 X 10 TYPE-I GLASS | 10 mg / 5 ml | 1 | 34800 |
| 268 | 2276 | Each 20ml of reconstituted suspension contains Paclitaxel, USP-100mg Albumin Human USP-900 mg | 1 X 25 Vials | Each 20ml of reconstituted suspension contains Paclitaxel, USP-100mg Albumin Human USP-900 mg (Both Nano particle Polymer based, and Human Albumin based are approved) | 1 | 3510 |
| 269 | 2279 | Erlotinib Tablets 150mg | 10 X10 Aluminium Blister Pack | 150mg | 100 | 8300 |
| 270 | 1629 | Fluconazole Tablets IP 200mg | 10 x 10 or 50x10 blister with aluminum foil pack | 200mg | 100 | 2470100 |
| 271 | 1808 | Flunarizine Tablets 5mg | 10 x 10 or 50x10 blister with aluminum foil pack | 5mg | 100 | 245700 |
| 272 | 2300 | Gemcitabine 200mg Injection vial | 1 X 25 Vials | 200mg vial | 1 | 11330 |
| 273 | 1367 | Human Albumin Solution I.P. 20percentage in100 ml bottle | 5 X 5X 4 | 20 Percentage in100 ml bottle | 1 | 42190 |
| 274 | 2305 | Hydroxy Urea Capsules 500mg | 10 X 10 Aluminium Blister Foil Pack | 500mg | 100 | 43700 |
| 275 | 2308 | Ifosphamide 1gm per vial | 1 X 25 Vials | 1gm per vial | 1 | 6540 |
| 276 | 2309 | IgM enriched Immunoglobulin IgM 12percentage, IgG 76percentage and IgA 12percentage concentrate 10ml | 1 X 10Ml Vials | IgM 12 Percentage, IgG 76 Percentage and IgA 12 Percentage concentrate 10ml | 1 | 2360 |
| 277 | 2098 | Imatinib Mesylate Tab 400mg(Addl. Indication) | 10 x 10 or 50 x 10 blister with aluminum foil pack or bottle of 10 capsules | 400mg(Addl. Indication) | 100 | 23400 |
| 278 | 1855 | Levamisole Tablets IP 150mg | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | 150mg | 100 | 6000 |
| 279 | 2330 | Lignocaine Hydrochloride Injection I.P. 5percentage w/ v | 1 X 25 Amps | 5 Percentage w/ v | 1 | 4950 |
| 280 | 1304 | Lipids I.V. 20percentage in 250ml Bottles | 250ML BOTTLE X 5 | 250ml | 1 | 4160 |
| 281 | 1874 | Methotrexate Tablets IP 2.5 mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 2.5 mg | 100 | 106700 |
| 282 | 1890 | Naloxone HCL Injection USP 400mcg/ml, 1ml amp | 1ml Amp 1x10x 10 or 1x10x5 Type-1 Glass | 400mcg/ml, 1ml amp | 1 | 1730 |
| 283 | 1470 | Oseltamivir Cap 75mg | 10 X 10 Blister with Aluminium Foil Pack | Each capsules contains Oseltamivir phosphate IP Equivalent to Oseltamivir 75mg | 1 | 61500 |
| 284 | 2372 | Oxaliplatin 100mg Injection vial | 1X 25 Vials | 100mg vial | 1 | 3170 |
| 285 | 2373 | Oxaliplatin 50mg Injection vial | 1X 25 Vials | 50mg vial | 1 | 1450 |
| 286 | 2374 | Paclitaxel Injection 260mg vial | 1X 25 Vials | 260mg vial | 1 | 7830 |
| 287 | 1907 | Paclitaxel Injection IP 30 mg / 5 ml | 30 mg /ml 5ml vial x 5 x10 or 5mlx 5x5 type-1 glass | 30 mg / 5 ml | 1 | 63150 |
| 288 | 2125 | Prazosin Tab 5mg | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | 5mg | 100 | 231800 |
| 289 | 2127 | Pregabalin SR 75mg plus Methyl cobalamin 1500mcg Tablets | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | Each Tablet contains Pregabalin SR 75mg plus Methyl cobalamin 1500mcg Tablets | 100 | 5634800 |
| 290 | 2126 | Pregabalin SR Tablet 75mg | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | Each Tablet contains Pregabalin SR 75mg | 100 | 6217800 |
| 291 | 2416 | Sacubitril plus Valsartan film coated Tablet 50mg | 10 X 10 or 5x10x10 Blister with Aluminum Foil Pack | 50mg | 100 | 58500 |
| 292 | 2140 | Sodium Valproate Tab 500mg | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | 500mg | 100 | 8379400 |
| 293 | 1959 | Tacrolimus Capsules 1mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 1mg | 100 | 47900 |
| 294 | 1971 | Trimetazidine Tablets 20mg | 10 X 1 0 (Or) 50 X 10 Blister WithAluminum Foil Pack | 20mg | 100 | 162000 |
| 295 | 2467 | Adrenaline Hydrochloride inj 0.001Percentage (intracameral) 1ml ampules | 1 X 10 or 1 X 25 | Adrenaline Hydrochloride inj 0.001 Percentage (intracameral) 1ml ampules | 1 | 1000 |
| 296 | 2488 | Calcium Acetate Tab 667mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 667mg | 100 | 436000 |
| 297 | 2469 | Carbachol 0.01Percentage Inj | 1 X 10 or 1 X 25 | Carbachol 0.01 Percentage Inj | 1 | 1200 |
| 298 | 2494 | Chlorthalidone Tab 6.25mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 6.25mg | 100 | 45000 |
| 299 | 2483 | Cilnidipine Tab 20mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 20mg | 100 | 168000 |
| 300 | 2485 | Clonidine Tab 100mcg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 100mcg | 100 | 300000 |
| 301 | 2471 | Hyalorunidase.Inj (Vial) | 1 X 10 or 1 X 25 | Hyalorunidase.Inj (Vial) | 1 | 8000 |
| 302 | 2474 | Lidocaine Inj 4Percentage (30.vial) | 1 X 10 or 1 X 25 | Lidocaine Inj 4 Percentage (30.vial) | 1 | 2000 |
| 303 | 2475 | Moxifloxacin plus Prednisolone acetate Eye Drops | 1 X 10 or 1 X 25 | Moxifloxacin plus Prednisolone acetate Eye Drops | 1 | 100000 |
| 304 | 2476 | Pilocarpine 2Percentage Eye Drops | 1 X 10 or 1 X 25 | Pilocarpine 2 Percentage Eye Drops | 1 | 5500 |
| 305 | 2484 | Prazosin Tab 1mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 1mg | 100 | 300000 |
| 306 | 2493 | Sodium bicarbonate Tab 1000mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 1000mg | 100 | 240000 |
| 307 | 2492 | Sodium bicarbonate Tab 500mg | 10 X 10 (or) 50 X 10 Blister WithAluminum Foil Pack | 500mg | 100 | 705000 |
| 308 | 1317 | Ondansetron Tablets IP 4 mg | 10 X 10 (or) 50 X 10 Blister With Aluminum Foil Pack | Ondansetron Tablets IP 4 mg | 100 | 5992000 |
| 309 | 632 | Antisnake Venom Injection | Each vial with 10ml water for injection | Snake venom antiserum IP polyvalent, enzyme refined, equine immunoglobulin. each 1ml upon reconstitution to 10ml with water for injection neutralizes not less than 0.60mg of dried Indian cobra(najanaja ) venom 0.45mg of dried. common krait ( bungaruscaeruleus) venom 0.60mg of dried , russells viper(baoiarusselli)venom 0.45mg of driedawsealedvipes (echiscartinatus) venom | 1 | 210000 |
| 310 | 40 | Ascorbic Acid Tablets IP (Chewable) 500 mg | 10 x 1 0 or 50 x 10 blister with aluminum foil pack. | 500 mg | 100 | 72279914 |
| 311 | 37 | Atenolol Tablets IP 50mg | 10x14 blister with aluminum foil pack | 50mg | 140 | 276786752 |
| 312 | 2066 | Atropine sulphate injection 0.6percentage , 10ml vials | 1x 5 x10 or 1x10x10 type-1 glass | 10ml vials | 1 | 155160 |
| 313 | 1754 | Chlorbutol+ Bezoncaine+ Turpentine Oil+ Paradichlorobenzene Benzine Ear Drops | 5ml x 5 x 5 or 10 x5 BFS / FFS | 5percentage chlorbutol + 2.7percentage Bezoncaine + 15percentage turpentine oil + 2percentage paradichlorobenzene benzene w/v 5 ml | 1 | 45900 |
| 314 | 107 | Chloroquine Phosphate Injection IP 40 mg / ml in 3ml amp | 2ml amp 10x10/ 5 x 10, type-1 glass | 40 mg / ml in 3ml amp | 1 | 158051 |
| 315 | 106 | Chloroquine Phosphate Tablets IP 250 mg base(Equivalent to 155 mg of Chloroquine ) | 10 x 10 or 50 x 10 blister with aluminum foil pack | 250 mg base(equivalent to 155 mg of chloroquine ) | 100 | 5370586 |
| 316 | 1626 | Chlorpheniramine Maleate Syrup 2 mg / 5ml in 60ml bottle | 60ml x 100, amber colour pet bottle | 2 mg / 5ml in 60ml bottle | 1 | 7245968 |
| 317 | 1627 | Clotrimazole Cream 2percentage IP 15gms Tube-Cream | 15gm x 10 x 10 (10 tubes tetra pack ) | 15gms | 1 | 972572 |
| 318 | 1215 | Dicyclomine Hcl Injection IP 10mg/ml in 2ml amp | 2ML AMP10X10 / 10X5 TYPE-1 GLASS | 10MG/ML IN 2ML AMP | 1 | 3366460 |
| 319 | 192 | Doxycycline HCL Capsule IP 100 mg | 10 x 1 0 or 50 x 10 blister with aluminum foil pack | 100 mg | 100 | 34848900 |
| 320 | 266 | Furosemide Injection , IP 10mg/1ml in 2 ml amp | 10 x 10 type-1 glass | 10mg/1ml in 2 ml amp | 1 | 1256936 |
| 321 | 1713 | IFA syrup | 5 x 10 bottles / 60ml x10x10 bottles | 1ml of ifa syrup containing 20mg of elemental iron and 100mcg of folic acid in 60ml in pet bottle with 1ml dropper | 1 | 8480366 |
| 322 | 1678 | Methyl Cobalamin Tablets 500mcg | 10 X 1 0 OR 50 X 10 ALUMINUM FOIL PACK | 500mcg | 100 | 70995418 |
| 323 | 513.01 | Oral Rehydration Salts IP (ORS) 20.5gm WHO formula with citrate salts | 20.5 gm pouch tri laminated aluminum foil cover with paper label | 20.5gm | 1 | 32919464 |
| 324 | 1319 | Pantoprazole (Enteric Coated) Tablets 40mg | 10 X 10 OR 50 X 10 BLISTER WITH ALUMINUM FOIL PACK | 40MG | 100 | 264308858 |
| 325 | 525 | Paracetamol Tablets IP 500 mg | 10 x 10 or 50 x 10 blister with aluminum foil pack | 500 mg | 100 | 456698000 |
| 326 | 564.01 | Promethazine Hcl Syrup IP 5 mg / 5 ml in 60ml | 60ML X 100 AMBER COLOUR PET BOTTLE | 5 MG / 5 ML IN 60ML | 1 | 186952 |
| 327 | 605 | Ranitidine Hcl (Film Coated) Tablets IP 150 mg | 10 x 1 0 or 50 x 10 aluminum foil pack | 150 mg | 100 | 2734800 |
| 328 | 655 | Water for Injection IP 10 ml amp | 1 x 50 | 10 ml amp | 1 | 2889320 |
| 329 | 30 | Acetazolamide Tablets IP 250 mg | 10 x 1 0 or 50 x 10 blister with aluminum foil pack. | 250 mg | 100 | 256742 |
| 330 | 1669 | Beastie Tablets IP 8 mg | 10 x 1 0 or 50 x 10 blister with aluminum foil pack. | 8 mg | 100 | 1976200 |
| 331 | 1752 | Cefuroxime Injection IP 250 mg vial | 250 mg vial | 250 mg | 1 | 26850 |
| 332 | 753 | Povidone Iodine Solution 5percentage , 500ml bottle | 500ML BOTTLE PACKING 500ML BOTTLE CARTON 20X 500ML | 5percentage , 500ml BOTTLE | 1 | 318036 |
| 333 | 1820 | Human Immunoglobulin IV 5 gm/100ml | Clear glass bottle mono pack | 5 gm/100ml | 1 | 5700 |
| 334 | 1966 | Tissue plasminogen activator TPA 40mg | TISSUE PLASMINOGEN ACTIVATOR TPA | 40MG | 1 | 1726 |

MANAGING DIRECTOR

Price Bid format